Sugi Predict

Sugi Predict / Compounds / Acetic Acid

Acetic Acid

Acetic Acid

SCHEMBL582377

CC(=O)O.COC1CC(=O)C=C2CC[C@H]3[C@@H]4CC[C@H](C(C)=O)[C@@]4(C)CC[C@@H]3[C@]21C

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.64
▸ CYP3A4 P08684 6/20 0.64
▸ SMN1; SMN2 Q16637 6/20 0.64
▸ SERPINA6 P08185 5/20 0.64
▸ LMNA P02545 4/20 0.64
▸ MAPT P10636 4/20 0.64
▸ MAPK1 P28482 3/20 0.64
▸ CYP2C9 P11712 2/20 0.64
▸ TSHR P16473 2/20 0.64
▸ HIF1A Q16665 2/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ ABCB11 O95342 2/20 0.64
▸ SHBG P04278 2/20 0.64
▸ NR3C2 P08235 2/20 0.64
▸ GPBAR1 Q8TDU6 2/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ KDM4E B2RXH2 1/20 0.64
▸ SLC22A2 O15244 1/20 0.64
▸ SLC22A1 O15245 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138289 0.98 ALDH1A1 (0.67) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
SCHEMBL6684640 0.90 CYP3A4 (0.61) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
SCHEMBL220822 0.89 ALDH1A1 (0.62) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
SCHEMBL9360183 0.89 CYP3A4 (0.62) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
SCHEMBL10893814 0.89 ALDH1A1 (0.62) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
Acetic Acid SCHEMBL2042107 0.87 CYP3A4 (0.65) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
Acetic Acid SCHEMBL4651980 0.87 SMN1; SMN2 (0.65) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
Water SCHEMBL15951778 0.86 ALDH1A1 (0.59) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
SCHEMBL28718285 0.86 CYP3A4 (0.59) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA
SCHEMBL4749451 0.86 ALDH1A1 (0.59) ALDH1A1CYP3A4SMN1; SMN2SERPINA6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 655 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1922094-B1 DEVICES FOR LYMPHATIC TARGETING LIU JIANG (CN) 2015-09-30 — — EP claimed
CN-104825397-A Controlled release delivery device containing organosol coating ISA ODIDI 2015-08-12 — — CN claimed
EP-2432535-A2 DRY POWDER INHALERS 3M Innovative Properties Company (US) 2012-03-28 — — EP claimed
WO-2010135340-A2 DRY POWDER INHALERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-11-25 — — WO claimed
US-20100278725-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING LIU, JIANG, DR. (CA) 2010-11-04 — — US claimed
US-20090263476-A1 Composition of Rapid Disintegrating Direct Compression Buccal Tablet PROVIDENT BANK 2009-10-22 — — US claimed
EP-2007360-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT Odidi, Isa (CA) 2008-12-31 — — EP claimed
EP-1922094-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING University Health Network (CA) 2008-05-21 — — EP claimed
WO-2007112581-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT ODIDI ISA (CA) 2007-10-11 — — WO claimed
WO-2007019678-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING UNIVERSITY HEALTH NETWORK (CA) 2007-02-22 — — WO claimed
EP-1100479-B1 MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF SCHIERHOLZ JOERG DR DR (DE) 2006-01-11 — — EP claimed
US-6641831-B1 Nondegradable; monolithic distribution of substances having different hydrophilicity dispersed in polymeric matrix SCHIERHOLZ JOERG (DE) 2003-11-04 — — US claimed
US-20030083497-A1 Taxoids, their preparation and pharmaceutical compositions containing them AVENTIS PHARMA, S.A. 2003-05-01 — — US claimed
US-20010021783-A1 New taxoids, their preparation and pharmaceutical compositions containing them Rhône-Poulenc Rorer S.A. 2001-09-13 — — US claimed
EP-0579435-B1 Cyclodextrin complexation CYCLOPS H F (IS) 1999-03-17 — — EP claimed
US-5472954-A Combining cyclodextrin with polymer before adding active material CYCLOPS H.F. (IS) 1995-12-05 — — US claimed
US-5324718-A Complexing with natural and synthetic polymers; high speed drug release CYCLOPS H.F. (IS) 1994-06-28 — — US claimed
EP-0579435-A1 Cyclodextrin complexation CYCLOPS h.f. (IS) 1994-01-19 — — EP claimed
CN-1041528-A HORMONE PREPARATION AND METHOD JENCAP RESEARCH LTD (CA) 1990-04-25 — — CN claimed
US-6372780-B1 — — None — — US disclosed
EP-4714407-A2 DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES Alcon Inc. (CH) 2026-03-25 — — EP disclosed
EP-3157408-B1 DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES ALCON INC (CH) 2026-03-25 — — EP disclosed
US-20260078219-A1 Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof ANP TECHNOLOGIES, INC. (US) 2026-03-19 — — US disclosed
US-20260053943-A1 NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF FULGENT GENETICS INC (US) 2026-02-26 — — US disclosed
US-12544342-B2 Pharmaceutical composition containing taxane nanoaggregates and use thereof FULGENT GENETICS, INC. (US) 2026-02-10 — — US disclosed
EP-3432940-B1 COMPLEX BRAIDED SCAFFOLDS FOR IMPROVED TISSUE REGENERATION BIOREZ INC (US) 2025-11-05 — — EP disclosed
US-20250213724-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac SE (DE) 2025-07-03 — — US disclosed
US-20250195443-A1 Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof ANP TECHNOLOGIES, INC. (US) 2025-06-19 — — US disclosed
US-20250144042-A1 COMPOSITIONS AND METHODS TO ACHIEVE SYSTEMIC UPTAKE OF PARTICLES FOLLOWING ORAL OR MUCOSAL ADMINISTRATION BROWN UNIVERSITY 2025-05-08 — — US disclosed
US-20250108106-A1 NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF FULGENT GENETICS, INC. 2025-04-03 — — US disclosed
US-20250057694-A1 DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES Ganihand, LLC (US) 2025-02-20 — — US disclosed
EP-3503927-B1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT UNIV CALIFORNIA (US) 2025-02-19 — — EP disclosed
EP-4493219-A1 POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF ANP Technologies, Inc. (US) 2025-01-22 — — EP disclosed
EP-3634507-B1 ORAL PROLONGED DRUG DELIVERY PLATFORMS EGY NANO PHARMA LP (EG) 2025-01-15 — — EP disclosed
US-12194294-B2 Oral drug delivery devices and methods using iontophoresis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-14 — — US disclosed
WO-2024229100-A2 NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF ANP TECHNOLOGIES, INC. (US) 2024-11-07 — — WO disclosed
US-12076409-B2 Polymer-drug conjugates for combination anticancer therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-09-03 — — US disclosed
US-12042561-B2 Hydrophobic molecule-induced branched polymer aggregates and their use ANP TECHNOLOGIES, INC. (US) 2024-07-23 — — US disclosed
EP-4188359-B1 DRUG COMBINATION AND ITS USE IN THE TREATMENT OF CANCER INDERES LTD (CY) 2024-07-17 — — EP disclosed
US-20240156964-A1 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE ARIZONA BOARD OF REGENTS 2024-05-16 — — US disclosed
US-20240044870-A1 METHODS AND REAGENTS FOR HIGH-THROUGHPUT DRUG SCREENING SINGLERON NANJING BIOTECHNOLOGIES LTD (CN) 2024-02-08 — — US disclosed
US-20240016754-A1 PHARMACEUTICAL COMPOSITION CONTAINING TAXANE NANOAGGREGATES AND USE THEREOF FULGENT GENETICS, INC. 2024-01-18 — — US disclosed
EP-4267753-A1 METHODS AND REAGENTS FOR HIGH-THROUGHPUT DRUG SCREENING Singleron (Nanjing) Biotechnologies, Ltd. (CN) 2023-11-01 — — EP disclosed
US-20230338579-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac SE (DE) 2023-10-26 — — US disclosed
WO-2023164487-A9 COMPOSITIONS AND METHODS TO ACHIEVE SYSTEMIC UPTAKE OF PARTICLES FOLLOWING ORAL OR MUCOSAL ADMINISTRATION BROWN UNIVERSITY (US) 2023-10-26 — — WO disclosed
US-11786597-B2 Ionic liquids for transdermal drug delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-17 — — US disclosed
US-20230302154-A1 NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF UNIVERSITY OF CONNECTICUT 2023-09-28 — — US disclosed
WO-2023177629-A1 POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF ANP TECHNOLOGIES, INC. (US) 2023-09-21 — — WO disclosed
WO-2023178038-A1 NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF FULGENT GENETICS, INC. (US) 2023-09-21 — — WO disclosed
US-20230277488-A1 DRUG COMBINATION AND ITS USE IN THE TREATMENT OF CANCER INDERES LTD (CY) 2023-09-07 — — US disclosed
WO-2023164487-A1 COMPOSITIONS AND METHODS TO ACHIEVE SYSTEMIC UPTAKE OF PARTICLES FOLLOWING ORAL OR MUCOSAL ADMINISTRATION BROWN UNIVERSITY (US) 2023-08-31 — — WO disclosed
EP-4188359-A1 DRUG COMBINATION AND ITS USE IN THE TREATMENT OF CANCER Inderes Ltd (CY) 2023-06-07 — — EP disclosed
US-11654114-B2 Oral prolonged drug delivery platforms EGY-NANO PHARMA, LP (EG) 2023-05-23 — — US disclosed
CN-109789216-B Topical skin treatment formulations based on ionic species 加利福尼亚大学董事会 2023-05-23 — — CN disclosed
CN-116157129-A Pharmaceutical combinations and their use in cancer treatment 因代雷斯有限公司 2023-05-23 — — CN disclosed
US-20230106657-A1 VEGETABLE POWDERS, METHODS FOR MANUFACTURING VEGETABLE POWDERS, AND KITS THEREOF QIZILBASH BILAL (US) 2023-04-06 — — US disclosed
EP-3082617-B1 HIGH-STRENGTH BIOABSORBABLE SUTURE TORNIER INC (US) 2022-11-16 — — EP disclosed
US-20220339259-A1 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF SHEN HAIFA (US) 2022-10-27 — — US disclosed
US-11446348-B2 Vegetable powders, methods for manufacturing vegetable powders, and kits thereof QIZILBASH BILAL (US) 2022-09-20 — — US disclosed
CN-114938632-A Use of MOG for initiating glioblastoma treatment 加利福尼亚大学董事会 2022-08-23 — — CN disclosed
WO-2022174171-A1 PHARMACEUTICAL COMPOSITION CONTAINING TAXANE NANOAGGREGATES AND USE THEREOF ANP TECHNOLOGIES, INC. (US) 2022-08-18 — — WO disclosed
US-11382731-B2 Medical devices with sealing properties COVIDIEN LP (US) 2022-07-12 — — US disclosed
WO-2022135481-A1 METHODS AND REAGENTS FOR HIGH-THROUGHPUT DRUG SCREENING SINGLERON (NANJING) BIOTECHNOLOGIES, LTD. (CN) 2022-06-30 — — WO disclosed
CN-114466658-A Orally delivered therapeutic compositions and uses thereof 沈海发 2022-05-10 — — CN disclosed
US-20220125820-A1 DRUG FORMULATIONS FOR CANCER TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-28 — — US disclosed
US-20220096645-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-31 — — US disclosed
EP-2261263-B1 PROCESSED STARCH POWDER WITH EXCELLENT DISINTEGRATION PROPERTIES AND MANUFACTURING METHOD THEREOF ASAHI CHEMICAL IND (JP) 2022-03-23 — — EP disclosed
US-11266395-B2 Devices and methods to provide hands free scleral depression during ophthalmic procedures Ganihand, LLC (US) 2022-03-08 — — US disclosed
WO-2022040435-A1 NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-02-24 — — WO disclosed
US-11254773-B2 Nanoscale multiple emulsions and nanoparticles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-22 — — US disclosed
WO-2022029555-A1 DRUG COMBINATION AND ITS USE IN THE TREATMENT OF CANCER INDERES LTD (CY) 2022-02-10 — — WO disclosed
EP-3925625-A1 HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE ANP Technologies, Inc. (US) 2021-12-22 — — EP disclosed
EP-3062819-B1 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY UNIV CALIFORNIA (US) 2021-12-22 — — EP disclosed
US-11197932-B2 Polymer-drug conjugates for combination anticancer therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-12-14 — — US disclosed
US-11191774-B2 Drug formulations for cancer treatment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-12-07 — — US disclosed
CN-113616661-A Neuroactive steroids, compositions and uses thereof 萨奇治疗股份有限公司 2021-11-09 — — CN disclosed
US-20210186880-A1 ORAL FORMULATIONS WITH INCREASED UPTAKE BROWN UNIVERSITY 2021-06-24 — — US disclosed
US-20210178089-A1 DRY POWDER INHALER DOSE COUNTERS ADAMIS PHARMACEUTICALS CORPORATION 2021-06-17 — — US disclosed
US-20210162050-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-06-03 — — US disclosed
US-20210162146-A1 POWDER FILLING PROCESSES ADAMIS PHARMACEUTICALS CORPORATION 2021-06-03 — — US disclosed
US-10953166-B2 Dry powder inhaler dose counters ADAMIS PHARMACEUTICALS CORPORATION (US) 2021-03-23 — — US disclosed
US-20210077665-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING LIU, JIANG (CA) 2021-03-18 — — US disclosed
WO-2021046497-A2 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF SHEN HAIFA (US) 2021-03-11 — — WO disclosed
EP-2661281-B1 HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE ANP TECH INC (US) 2021-03-10 — — EP disclosed
US-10940276-B2 Powder filling processes ADAMIS PHARMACEUTICALS CORPORATION (US) 2021-03-09 — — US disclosed
US-20210059939-A1 Hydrophobic Molecule-Induced Branched Polymer Aggregates and their Use FULGENT GENETICS, INC. 2021-03-04 — — US disclosed
US-10918740-B2 RNA containing composition for treatment of tumor diseases CUREVAC AG (DE) 2021-02-16 — — US disclosed
US-10912834-B2 Topical formulations based on ionic species for skin treatment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-02-09 — — US disclosed
US-10869935-B2 RNA containing composition for treatment of tumor diseases CUREVAC AG (DE) 2020-12-22 — — US disclosed
US-20200392289-A1 Biodegradable Polymer and Use Thereof FULGENT GENETICS, INC. 2020-12-17 — — US disclosed
US-20200385503-A1 NANOSCALE MULTIPLE EMULSIONS AND NANOPARTICLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-12-10 — — US disclosed
EP-2861285-B1 METERED DOSE DISPENSING VALVE 3M INNOVATIVE PROPERTIES CO (US) 2020-11-25 — — EP disclosed
US-10806700-B2 Oral dosage forms for delivery of therapeutic agents COVIDIEN LP (US) 2020-10-20 — — US disclosed
US-20200306029-A1 COMPLEX BRAIDED SCAFFOLDS FOR IMPROVED TISSUE REGENERATION BIOREZ, INC. (US) 2020-10-01 — — US disclosed
US-20200306284-A1 DRUG FORMULATIONS FOR CANCER TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-10-01 — — US disclosed
US-20200297858-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-24 — — US disclosed
CN-107007875-B Enzyme and temperature dual-responsiveness drug-loaded hydrogel and preparation method and application thereof 中国人民解放军军事医学科学院野战输血研究所 2020-09-22 — — CN disclosed
US-20200238081-A1 ORAL DRUG DELIVERY DEVICES AND METHODS USING IONTOPHORESIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-07-30 — — US disclosed
US-20200197306-A1 CATIONIC LIQUID CRYSTALLINE NANOPARTICLES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-25 — — US disclosed
EP-2288340-B1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE LLC (US) 2020-06-24 — — EP disclosed
US-10688048-B2 Hydrophobic molecule-induced branched polymer aggregates and their use ANP TECHNOLOGIES, INC. (US) 2020-06-23 — — US disclosed
US-20200170640-A1 HIGH-STRENGTH BIOABSORBABLE SUTURE HOWMEDICA OSTEONICS CORP. 2020-06-04 — — US disclosed
US-20200163894-A1 ORAL PROLONGED DRUG DELIVERY PLATFORMS CNH INDUSTRIAL AMERICA LLC 2020-05-28 — — US disclosed
US-10653789-B2 Polymer-drug conjugates for combination anticancer therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-05-19 — — US disclosed
US-10624877-B2 Composition and method for treatment of symptoms associated with various skin conditions THERACEUTIX, LLC (US) 2020-04-21 — — US disclosed
US-10624858-B2 Controlled release composition using transition coating, and method of preparing same INTELLIPHARMACEUTICS CORP (CA) 2020-04-21 — — US disclosed
EP-3634386-A1 CATIONIC LIQUID CRYSTALLINE NANOPARTICLES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-04-15 — — EP disclosed
EP-3634507-A1 ORAL PROLONGED DRUG DELIVERY PLATFORMS EGY-Nano Pharma, LP (EG) 2020-04-15 — — EP disclosed
EP-3615011-A1 PHARMACEUTICAL COMPOSITION FOR IN VIVO DELIVERY, METHOD OF PREPARATION OF A SUBSTANTIALLY WATERINSOLUBLE PHARMACOLOGICALLY ACTIVE AGENT ZY Therapeutics Inc. (US) 2020-03-04 — — EP disclosed
EP-2416650-B1 NANOPARTICLE FORMULATIONS AND USES THEROF ABRAXIS BIOSCIENCE LLC (US) 2020-02-26 — — EP disclosed
US-20200054563-A1 PHARMACEUTICAL COMPOSITION FOR IN VIVO DELIVERY, METHOD OF PREPARATION OF A SUBSTANTIALLY WATER-INSOLUBLE PHARMACOLOGICALLY ACTIVE AGENT FOR IN VIVO DELIVERY, AND METHOD OF TREATING DISEASE ZY THERAPEUTICS INC. (US) 2020-02-20 — — US disclosed
WO-2020028909-A1 ORAL FORMULATIONS WITH INCREASED UPTAKE BROWN UNIVERSITY (US) 2020-02-06 — — WO disclosed
EP-3603661-A2 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac AG (DE) 2020-02-05 — — EP disclosed
CN-110753541-A Pharmaceutical compositions for in vivo delivery, process for preparing substantially water insoluble pharmacologically active agents ZY治疗公司 2020-02-04 — — CN disclosed
EP-3260152-B1 DRY POWDER INHALERS ADAMIS PHARMACEUTICALS CORP (US) 2019-12-18 — — EP disclosed
US-10449254-B2 Ionic liquids for transdermal drug delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-10-22 — — US disclosed
US-20190255265-A1 DRY POWDER INHALERS 3M INNOVATIVE PROPERTIES COMPANY 2019-08-22 — — US disclosed
US-10376662-B2 Dry powder inhalers ADAMIS PHARMACEUTICALS CORPORATION (US) 2019-08-13 — — US disclosed
EP-3061471-B1 MEDICAL DEVICES WITH SEALING PROPERTIES COVIDIEN LP (US) 2019-07-31 — — EP disclosed
US-20190201466-A1 VEGETABLE POWDERS, METHODS FOR MANUFACTURING VEGETABLE POWDERS, AND KITS THEREOF QIZILBASH BILAL (US) 2019-07-04 — — US disclosed
EP-3503927-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT The Regents of the University of California (US) 2019-07-03 — — EP disclosed
US-10335562-B2 Metered dose dispensers with porous body 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-07-02 — — US disclosed
US-20190192661-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-06-27 — — US disclosed
EP-3326641-B1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CUREVAC AG (DE) 2019-06-26 — — EP disclosed
EP-3173092-B1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CUREVAC AG (DE) 2019-06-26 — — EP disclosed
US-10314787-B2 Controlled release delivery device comprising an organosol coat INTELLIPHARMACEUTICS CORPORATION (CA) 2019-06-11 — — US disclosed
US-20190151469-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac SE (DE) 2019-05-23 — — US disclosed
US-10293058-B2 RNA containing composition for treatment of tumor diseases CUREVAC AG (DE) 2019-05-21 — — US disclosed
CN-109789216-A Skin treating topical formulations based on ionic species 加利福尼亚大学董事会 2019-05-21 — — CN disclosed
EP-2043718-B1 METERED DOSE DISPENSERS 3M INNOVATIVE PROPERTIES CO (US) 2019-03-27 — — EP disclosed
US-20190083399-A9 DRUG DELIVERY COMPOSITION INTELLIPHARMACEUTICS CORPORATION (CA) 2019-03-21 — — US disclosed
US-20190076363-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT INTELLIPHARMACEUTICS CORPORATION (CA) 2019-03-14 — — US disclosed
EP-2387956-B1 Anchoring device COVIDIEN LP (US) 2019-03-13 — — EP disclosed
US-20190054189-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CUREVAC AG (DE) 2019-02-21 — — US disclosed
EP-3432940-A2 COMPLEX BRAIDED SCAFFOLDS FOR IMPROVED TISSUE REGENERATION Biorez, Inc. (US) 2019-01-30 — — EP disclosed
US-10159649-B2 Controlled release delivery device comprising an organosol coat INTELLIPHARMACEUTICS CORPORATION (CA) 2018-12-25 — — US disclosed
WO-2018226383-A1 ORAL PROLONGED DRUG DELIVERY PLATFORMS EGY-NANO PHARMA, LP (EG) 2018-12-13 — — WO disclosed
WO-2018226975-A1 CATIONIC LIQUID CRYSTALLINE NANOPARTICLES BOARD OF REGENTS, THE UNIVESTIY OF TEXAS SYSTEM (US) 2018-12-13 — — WO disclosed
WO-2018209293-A2 NANOSCALE MULTIPLE EMULSIONS AND NANOPARTICLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-11-15 — — WO disclosed
US-20180311448-A1 POWDER FILLING PROCESSES 3M INNOVATIVE PROPERTIES COMPANY 2018-11-01 — — US disclosed
WO-2018200393-A1 PHARMACEUTICAL COMPOSITION FOR IN VIVO DELIVERY, METHOD OF PREPARATION OF A SUBSTANTIALLY WATERINSOLUBLE PHARMACOLOGICALLY ACTIVE AGENT ZY THERAPEUTICS INC. (US) 2018-11-01 — — WO disclosed
US-20180289620-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2018-10-11 — — US disclosed
EP-3380082-A2 DRUG FORMULATIONS FOR CANCER TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-10-03 — — EP disclosed
CN-104755122-B Quantitative distribution valve 3M创新有限公司 2018-09-28 — — CN disclosed
EP-2982315-B1 CUTTING TEMPLATE AND METHOD FOR A HEMOSTATIC PATCH COVIDIEN LP (US) 2018-09-26 — — EP disclosed
US-20180256662-A1 PRODUCT AND METHOD OF DEPLOYING KALE DERIVATIVES FOR ANTI-CANCER EFFECTS QIZILBASH BILAL (US) 2018-09-13 — — US disclosed
US-20180250479-A1 DRY POWDER INHALER DOSE COUNTERS 3M INNOVATIVE PROPERTIES COMPANY 2018-09-06 — — US disclosed
US-10058326-B2 Anchoring device COVIDIEN LP (US) 2018-08-28 — — US disclosed
US-20180235884-A1 Hydrophobic Molecule-Induced Branched Polymer Aggregates and their Use FULGENT GENETICS, INC. 2018-08-23 — — US disclosed
US-20180207295-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CUREVAC AG (DE) 2018-07-26 — — US disclosed
US-10022508-B2 Powder filling processes ADAMIS PHARMACEUTICALS CORPORATION (US) 2018-07-17 — — US disclosed
EP-3332826-A1 DRY POWDER INHALER WITH A DOSE COUNTER Adamis Pharmaceuticals Corporation (US) 2018-06-13 — — EP disclosed
US-9987442-B2 Dry powder inhaler dose counters ADAMIS PHARMACEUTICALS CORPORATION (US) 2018-06-05 — — US disclosed
EP-3326641-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac AG (DE) 2018-05-30 — — EP disclosed
CN-108064176-A Compositions comprising RNA for the treatment of neoplastic diseases 库瑞瓦格股份公司 2018-05-22 — — CN disclosed
US-20180133196-A1 COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS THERACEUTIX, LLC 2018-05-17 — — US disclosed
US-9968590-B2 Composition and method for treatment of symptoms associated with various skin conditions THERACEUTIX, LLC (US) 2018-05-15 — — US disclosed
US-9919016-B2 Product and method of deploying kale derivatives for anti-cancer effects QIZILBASH BILAL (US) 2018-03-20 — — US disclosed
WO-2018044920-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-08 — — WO disclosed
US-20180036419-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-02-08 — — US disclosed
EP-2468255-B1 Biodegradable osmotic pump implant for drug delivery CONFLUENT SURGICAL INC (US) 2018-01-31 — — EP disclosed
EP-2432534-B1 DRY POWDER INHALER DOSE COUNTERS ADAMIS PHARMACEUTICALS CORP (US) 2018-01-17 — — EP disclosed
EP-3267975-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY The Regents of the University of California (US) 2018-01-17 — — EP disclosed
EP-3266450-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF Abraxis BioScience, LLC (US) 2018-01-10 — — EP disclosed
US-20170367978-A1 AQUEOUS TOPICAL DRUG FORMULATION WITH CONTROLLED RELEASE AND INCREASED STABILITY PHOSPHOREX, INC. (US) 2017-12-28 — — US disclosed
EP-3260152-A1 DRY POWDER INHALERS Adamis Pharmaceuticals Corporation (US) 2017-12-27 — — EP disclosed
US-20170273775-A1 COMPLEX BRAIDED SCAFFOLDS FOR IMPROVED TISSUE REGENERATION BIOREZ, INC. 2017-09-28 — — US disclosed
WO-2017165889-A2 COMPLEX BRAIDED SCAFFOLDS FOR IMPROVED TISSUE REGENERATION BIOREZ, INC. (US) 2017-09-28 — — WO disclosed
EP-2432535-B1 DRY POWDER INHALERS ADAMIS PHARMACEUTICALS CORP (US) 2017-09-20 — — EP disclosed
US-9694149-B2 Manufacture of medicinal aerosol canisters 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-07-04 — — US disclosed
US-20170172975-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2017-06-22 — — US disclosed
US-20170156727-A1 HIGH-STRENGTH BIOABSORBABLE SUTURE HOWMEDICA OSTEONICS CORP. 2017-06-08 — — US disclosed
WO-2017091767-A2 DRUG FORMULATIONS FOR CANCER TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-06-01 — — WO disclosed
EP-3173092-A2 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac AG (DE) 2017-05-31 — — EP disclosed
US-9642946-B2 Medical device with intrapore films COVIDIEN LP (US) 2017-05-09 — — US disclosed
US-20170112770-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT INTELLIPHARMACEUTICS CORPORATION (CA) 2017-04-27 — — US disclosed
EP-3157408-A2 DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES Ganiban, Gary (US) 2017-04-26 — — EP disclosed
EP-2768561-B1 METHOD OF MANUFACTURING MEDICINAL AEROSOL CANISTERS AS WELL AS THE DISPENSER COMPRISING SAID CANISTER 3M INNOVATIVE PROPERTIES CO (US) 2017-04-26 — — EP disclosed
US-20170105873-A1 MINIMALLY INVASIVE APPARATUS AND METHOD FOR TREATING THE RETINA MAZZOCCHI RUDY A (US) 2017-04-20 — — US disclosed
US-20170080169-A1 DRY POWDER INHALERS 3M INNOVATIVE PROPERTIES COMPANY 2017-03-23 — — US disclosed
CN-103889490-B Manufacture of medicinal aerosol cans 3M创新有限公司 2017-02-15 — — CN disclosed
US-9561188-B2 Controlled release delivery device comprising an organosol coat INTELLIPHARMACEUTICS CORPORATION (CA) 2017-02-07 — — US disclosed
US-9532902-B2 Minimally-invasive method and apparatus for restructuring the retina Optistent, Inc. (US) 2017-01-03 — — US disclosed
US-20160338950-A1 Oral Dosage Forms for Delivery of Therapeutic Agents TYCO HEALTHCARE GROUP LP 2016-11-24 — — US disclosed
US-20160331844-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CureVac SE (DE) 2016-11-17 — — US disclosed
EP-2922770-B1 METERED DOSE DISPENSING VALVE 3M INNOVATIVE PROPERTIES CO (US) 2016-11-02 — — EP disclosed
WO-2016170176-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES CUREVAC AG (DE) 2016-10-27 — — WO disclosed
EP-3082617-A1 HIGH-STRENGTH BIOABSORBABLE SUTURE Tornier, Inc. (US) 2016-10-26 — — EP disclosed
US-9474870-B2 Dry powder inhalers ADAMIS PHARMACEUTICALS CORPORATION (US) 2016-10-25 — — US disclosed
US-20160262749-A1 ANCHORING DEVICE TYCO HEALTHCARE GROUP LP 2016-09-15 — — US disclosed
WO-2016145096-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-09-15 — — WO disclosed
US-20160263225-A1 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE ARIZONA BOARD OF REGENTS 2016-09-15 — — US disclosed
EP-3062819-A2 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY The Regents of The University of California (US) 2016-09-07 — — EP disclosed
EP-1944019-B1 Method for the preparation of protein stabilized pharmacologically active agents ABRAXIS BIOSCIENCE LLC (US) 2016-09-07 — — EP disclosed
US-20160250013-A1 MEDICAL DEVICES WITH SEALING PROPERTIES COVIDIEN LP 2016-09-01 — — US disclosed
EP-3061471-A1 MEDICAL DEVICES WITH SEALING PROPERTIES Covidien LP (US) 2016-08-31 — — EP disclosed
EP-2368522-B1 Therapeutic implant COVIDIEN LP (US) 2016-08-31 — — EP disclosed
EP-2368523-B1 Therapeutic Implant COVIDIEN LP (US) 2016-08-31 — — EP disclosed
US-9421169-B2 Oral dosage forms for delivery of therapeutic agents COVIDIEN LP (US) 2016-08-23 — — US disclosed
US-20160235799-A1 PRODUCT AND METHOD OF DEPLOYING KALE DERIVATIVES FOR ANTI-CANCER EFFECTS QIZILBASH BILAL (US) 2016-08-18 — — US disclosed
EP-1996173-B1 POWDER FILLING PROCESSES ADAMIS PHARMACEUTICALS CORP (US) 2016-06-22 — — EP disclosed
WO-2016094617-A1 AQUEOUS TOPICAL DRUG FORMULATION WITH CONTROLLED RELEASE AND INCREASED STABILITY PHOSPHOREX, INC. (US) 2016-06-16 — — WO disclosed
US-9358002-B2 Anchoring device COVIDIEN LP (US) 2016-06-07 — — US disclosed
US-20160151325-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF ABRAXIS BIOSCIENCE LLC (US) 2016-06-02 — — US disclosed
EP-2368521-B1 Therapeutic implant COVIDIEN LP (US) 2016-03-16 — — EP disclosed
EP-2982315-A1 CUTTING TEMPLATE AND METHOD FOR A HEMOSTATIC PATCH Covidien LP (US) 2016-02-10 — — EP disclosed
US-20160000881-A1 Oral Drug Devices and Drug Formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-01-07 — — US disclosed
WO-2015195748-A2 DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES GANIBAN GARY (US) 2015-12-23 — — WO disclosed
US-20150359529-A1 DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES ALCON INC. (CH) 2015-12-17 — — US disclosed
US-20150359948-A1 MEDICAL DEVICE WITH INTRAPORE FILMS TYCO HEALTHCARE GROUP LP 2015-12-17 — — US disclosed
US-20150342604-A1 SOFT TISSUE GRAFT PREPARATION DEVICES AND METHODS COVIDIEN LP (US) 2015-12-03 — — US disclosed
US-20150335836-A1 DRY POWDER INHALER DOSE COUNTERS ADAMIS PHARMACEUTICALS CORPORATION 2015-11-26 — — US disclosed
EP-2478848-B1 Cutting template and method for a hemostatic patch COVIDIEN LP (US) 2015-11-04 — — EP disclosed
US-20150306321-A1 METERED DOSE DISPENSING VALVE 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-10-29 — — US disclosed
EP-2922770-A1 METERED DOSE DISPENSING VALVE 3M Innovative Properties Company (US) 2015-09-30 — — EP disclosed
EP-1922094-B1 DEVICES FOR LYMPHATIC TARGETING LIU JIANG (CN) 2015-09-30 — — EP disclosed
US-9144634-B2 Medical device with intrapore films COVIDIEN LP (US) 2015-09-29 — — US disclosed
WO-2015066647-A9 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-09-17 — — WO disclosed
US-9125999-B2 Dry powder inhaler dose counters ADAMIS PHARMACEUTICALS CORPORATION (US) 2015-09-08 — — US disclosed
US-20150238435-A1 Oral Drug Devices and Drug Formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-08-27 — — US disclosed
CN-104825397-A Controlled release delivery device containing organosol coating ISA ODIDI 2015-08-12 — — CN disclosed
US-20150217065-A1 DRY POWDER INHALERS ADAMIS PHARMACEUTICALS CORPORATION 2015-08-06 — — US disclosed
US-20150190593-A1 POWDER FILLING PROCESSES ADAMIS PHARMACEUTICALS CORPORATION (US) 2015-07-09 — — US disclosed
CN-104755122-A Quantitative distribution valve 3M INNOVATIVE PROPERTIES CO 2015-07-01 — — CN disclosed
US-9067031-B2 Metered dose valves and dispensers 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-06-30 — — US disclosed
WO-2015094619-A1 HIGH-STRENGTH BIOABSORBABLE SUTURE TORNIER, INC. (US) 2015-06-25 — — WO disclosed
US-20150136122-A1 Metered Dose Dispensing Valve KINDEVA DRUG DELIVERY L.P. 2015-05-21 — — US disclosed
CN-102056596-B Nanoparticle formulations and uses thereof ABRAXIS BIOSCIENCES LLC 2015-05-20 — — CN disclosed
US-9034011-B2 Anchoring device COVIDIEN LP (US) 2015-05-19 — — US disclosed
US-9029427-B2 Controlled release solid preparation ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-05-12 — — US disclosed
WO-2015066647-A2 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-05-07 — — WO disclosed
US-9023081-B2 Knotted suture end effector COVIDIEN LP (US) 2015-05-05 — — US disclosed
US-9017379-B2 Knotted suture end effector COVIDIEN LP (US) 2015-04-28 — — US disclosed
US-20150111960-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF ABRAXIS BIOSCIENCE LLC (US) 2015-04-23 — — US disclosed
EP-2861285-A1 METERED DOSE DISPENSING VALVE 3M Innovative Properties Company (US) 2015-04-22 — — EP disclosed
EP-2368501-B1 Knotted suture end effector COVIDIEN LP (US) 2015-04-22 — — EP disclosed
US-9012467-B2 Compositions for intratumoral administration COVIDIEN LP (US) 2015-04-21 — — US disclosed
US-20150104521-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2015-04-16 — — US disclosed
EP-2859888-A1 Powder filled elongate carrier 3M Innovative Properties Company (US) 2015-04-15 — — EP disclosed
US-8997799-B2 Powder filling processes ADAMIS PHARMACEUTICALS CORPORATION (US) 2015-04-07 — — US disclosed
US-8985102-B2 Dry powder inhalers ADAMIS PHARMACEUTICALS CORPORATION (US) 2015-03-24 — — US disclosed
US-8980302-B2 Therapeutic implant COVIDIEN LP (US) 2015-03-17 — — US disclosed
CN-102458543-B Dry powder inhalers 3M INNOVATIVE PROPERTIES CO 2015-02-04 — — CN disclosed
EP-2377470-B1 Tapered looped suture COVIDIEN LP (US) 2015-01-21 — — EP disclosed
US-8932618-B2 Biodegradable osmotic pump implant for drug delivery CONFLUENT SURGICAL, INC. (US) 2015-01-13 — — US disclosed
EP-2807983-A1 Tapered looped suture Covidien LP (US) 2014-12-03 — — EP disclosed
EP-2007360-B1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT ODIDI ISA (CA) 2014-11-26 — — EP disclosed
EP-2476444-B1 Medical device with intrapore films COVIDIEN LP (US) 2014-11-05 — — EP disclosed
US-20140314664-A1 Hydrophobic Molecule-Induced Branched Polymer Aggregates And Their Use ANP TECHNOLOGIES, INC. (US) 2014-10-23 — — US disclosed
US-20140299128-A1 MANUFACTURE OF MEDICINAL AEROSOL CANISTERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-10-09 — — US disclosed
US-20140302163-A1 Water With Improved Transdermal and Cellular Delivery Properties and Methods Of Manufacture And Use Thereof Subtech Industries, LLC (US) 2014-10-09 — — US disclosed
US-20140302157-A1 NANOPARTICLE FORMULATIONS AND USES THEROF ABRAXIS BIOSCIENCE, LLC (US) 2014-10-09 — — US disclosed
US-8853260-B2 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, LLC (US) 2014-10-07 — — US disclosed
WO-2014160404-A1 IMPROVED ORAL DRUG DEVICES AND DRUG FORMULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-02 — — WO disclosed
WO-2014145352-A1 WATER WITH IMPROVED TRANSDERMAL AND CELLULAR DELIVERY SUBTECH INDUSTRIES LLC (US) 2014-09-18 — — WO disclosed
US-20140248329-A1 Therapeutic Implant COVIDIEN LP (US) 2014-09-04 — — US disclosed
US-8821938-B2 Porous drug matrices and methods of manufacture thereof ACUSPHERE, INC. (US) 2014-09-02 — — US disclosed
EP-2768561-A1 MANUFACTURE OF MEDICINAL AEROSOL CANISTERS 3M Innovative Properties Company (US) 2014-08-27 — — EP disclosed
US-20140212362-A1 COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS THERACEUTIX, LLC (US) 2014-07-31 — — US disclosed
CN-103889490-A Manufacture of medicinal aerosol cans 3M INNOVATIVE PROPERTIES CO 2014-06-25 — — CN disclosed
US-8758798-B2 Therapeutic implant COVIDIEN LP (US) 2014-06-24 — — US disclosed
US-8758800-B2 Therapeutic implant COVIDIEN LP (US) 2014-06-24 — — US disclosed
US-8758799-B2 Therapeutic implant COVIDIEN LP (US) 2014-06-24 — — US disclosed
WO-2014081746-A1 METERED DOSE DISPENSING VALVE 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-05-30 — — WO disclosed
WO-2014074605-A1 PRESERVED TOPICAL FORMULATIONS WITH IMPROVED ANTIMICROBIAL ACTIVITY ALLERGAN, INC. (US) 2014-05-15 — — WO disclosed
US-20140127327-A1 PRESERVED TOPICAL FORMULATIONS WITH IMPROVED ANTIMICROBIAL ACTIVITY ALLERGAN, INC. (US) 2014-05-08 — — US disclosed
US-20140080901-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2014-03-20 — — US disclosed
WO-2013188609-A1 METERED DOSE DISPENSING VALVE 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-12-19 — — WO disclosed
EP-2387955-B1 Anchoring device COVIDIEN LP (US) 2013-11-13 — — EP disclosed
EP-2661281-A2 HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE ANP Technologies, Inc. (US) 2013-11-13 — — EP disclosed
US-20130296833-A1 BIODEGRADABLE OSMOTIC PUMP IMPLANT FOR DRUG DELIVERY CONFLUENT SURGICAL, INC. 2013-11-07 — — US disclosed
US-20130274352-A1 Oral Drug Devices and Drug Formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2013-10-17 — — US disclosed
US-8557861-B2 Low oil emulsion compositions for delivering taxoids and other insoluble drugs MAST THERAPEUTICS, INC. (US) 2013-10-15 — — US disclosed
EP-1023050-B1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF ABRAXIS BIOSCIENCE LLC (US) 2013-09-25 — — EP disclosed
US-8518440-B2 Biodegradable osmotic pump implant for drug delivery CONFLUENT SURGICAL, INC. (US) 2013-08-27 — — US disclosed
US-20130195983-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2013-08-01 — — US disclosed
US-8468708-B2 Hemostatic patch CONFLUENT SURGICAL, INC. (US) 2013-06-25 — — US disclosed
US-8470873-B2 Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof MAST THERAPEUTICS, INC. (US) 2013-06-25 — — US disclosed
US-8440726-B2 Mixture of oily oleates, a polyoxyethylene sorbitan fatty ester, liquid polyhydric alcohol, acidic phospholipids of saturated/ unsaturated fatty acids; self-(micro)emulsification drug delivery system pre-concentrate; stability; high dispersion rate; small particle size; bioavailability; antitumoragents NOF CORPORATION (JP) 2013-05-14 — — US disclosed
US-8431618-B2 Processed starch powder with excellent disintegration properties and manufacturing method thereof ASAHI KASEI CHEMICALS CORPORATION (JP) 2013-04-30 — — US disclosed
WO-2013059409-A1 MANUFACTURE OF MEDICINAL AEROSOL CANISTERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-04-25 — — WO disclosed
WO-2013049272-A2 COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS THERACEUTIX, LLC (US) 2013-04-04 — — WO disclosed
US-20130079822-A1 Knotted Suture End Effector COVIDIEN LP (US) 2013-03-28 — — US disclosed
US-20130072973-A1 Knotted Suture End Effector COVIDIEN LP (US) 2013-03-21 — — US disclosed
US-20130046382-A1 MINIMALLY-INVASIVE METHOD AND APPARATUS FOR RESTRUCTURING THE RETINA MAZZOCCHI RUDY A (US) 2013-02-21 — — US disclosed
US-20130025428-A1 Hemostatic Patch CONFLUENT SURGICAL, INC. (US) 2013-01-31 — — US disclosed
US-20130030282-A1 SYNTHESIS AND CHARACTERIZATION OF NEAR IR FLUORESCENT MAGNETIC AND NON-MAGNETIC ALBUMIN NANOPARTICLES FOR BIOMEDICAL APPLICATIONS BAR ILAN UNIVERSITY (IL) 2013-01-31 — — US disclosed
EP-2538876-A2 MINIMALLY-INVASIVE METHOD AND APPARATUS FOR RESTRUCTURING THE RETINA Mazzocchi, Rudy A. (US) 2013-01-02 — — EP disclosed
CN-101011355-B Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof CHEN ANDREW XIAN 2013-01-02 — — CN disclosed
US-8323316-B2 Knotted suture end effector COVIDIEN LP (US) 2012-12-04 — — US disclosed
US-8302323-B2 Hemostatic patch CONFLUENT SURGICAL, INC. (US) 2012-11-06 — — US disclosed
US-20120248658-A1 System and Method for Formation of Biodegradable Ultra-Porous Hollow Fibers and Use Thereof COVIDIEN LP 2012-10-04 — — US disclosed
EP-2505213-A2 System and method for formation of biodegradable ultra-porous hollow fibers and use thereof Tyco Healthcare Group LP (US) 2012-10-03 — — EP disclosed
US-20120231082-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF DESAI NEIL P (US) 2012-09-13 — — US disclosed
EP-2491871-A1 Anchoring device Tyco Healthcare Group LP (US) 2012-08-29 — — EP disclosed
EP-0961612-B2 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS AND THEIR USE ABRAXIS BIOSCIENCE LLC (US) 2012-08-01 — — EP disclosed
EP-2478848-A2 Hemostatic patch Confluent Surgical, Inc. (US) 2012-07-25 — — EP disclosed
US-20120183583-A1 Medical Device With Intrapore Films COVIDIEN LP 2012-07-19 — — US disclosed
EP-2476444-A2 Medical device with intrapore films Tyco Healthcare Group LP (US) 2012-07-18 — — EP disclosed
WO-2012094620-A2 HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE ANP TECHNOLOGIES, INC. (US) 2012-07-12 — — WO disclosed
EP-2468255-A2 Biodegradable osmotic pump implant for drug delivery Confluent Surgical, Inc. (US) 2012-06-27 — — EP disclosed
US-20120152245-A1 DRY POWDER INHALER DOSE COUNTERS ADAMIS PHARMACEUTICALS CORPORATION 2012-06-21 — — US disclosed
US-20120156289-A1 Biodegradable Osmotic Pump Implant For Drug Delivery CONFLUENT SURGICAL, INC. (US) 2012-06-21 — — US disclosed
US-20120132203-A1 DRY POWDER INHALERS ADAMIS PHARMACEUTICALS CORPORATION 2012-05-31 — — US disclosed
EP-2432534-A2 DRY POWDER INHALER DOSE COUNTERS 3M Innovative Properties Company (US) 2012-03-28 — — EP disclosed
EP-2432535-A2 DRY POWDER INHALERS 3M Innovative Properties Company (US) 2012-03-28 — — EP disclosed
US-8137684-B2 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, LLC (US) 2012-03-20 — — US disclosed
US-20120045504-A1 ORAL DRUG DEVICES AND DRUG FORMULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-02-23 — — US disclosed
EP-2419085-A2 IMPROVED ORAL DRUG DEVICES AND DRUG FORMULATIONS The Regents of the University of California (US) 2012-02-22 — — EP disclosed
EP-2416650-A1 NANOPARTICLE FORMULATIONS AND USES THEROF Abraxis BioScience, LLC (US) 2012-02-15 — — EP disclosed
EP-1946780-B1 CONTROLLED RELEASE SOLID PREPARATION ASAHI KASEI CHEMICALS CORP (JP) 2012-01-11 — — EP disclosed
US-20110313450-A1 HEMOSTATIC PATCH COVIDIEN LP 2011-12-22 — — US disclosed
US-20110313406-A1 HEMOSTATIC PATCH CONFLUENT SURGICAL, INC. (US) 2011-12-22 — — US disclosed
US-20110293690-A1 Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof TYCO HEALTHCARE GROUP LP (US) 2011-12-01 — — US disclosed
EP-2389928-A2 Biodegradable polymer encapsulated microsphere particulate film and method of making thereof Tyco Healthcare Group LP (US) 2011-11-30 — — EP disclosed
EP-2387991-A1 Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof Adventrx Pharmaceuticals, Inc. (US) 2011-11-23 — — EP disclosed
EP-2387956-A1 Anchoring device Tyco Healthcare Group LP (US) 2011-11-23 — — EP disclosed
EP-2387955-A1 Anchoring device Tyco Healthcare Group LP (US) 2011-11-23 — — EP disclosed
EP-2386290-A2 Modulating drug release rate by controlling the kinetics of the pH transition in hydrogels Confluent Surgical Inc. (US) 2011-11-16 — — EP disclosed
US-20110254393-A1 ELECTRIC MOTOR DEVICE DENSO CORPORATION (JP) 2011-10-20 — — US disclosed
US-20110254749-A1 ANTENNA APPARATUS INCLUDING MULTIPLE ANTENNA PORTIONS ON ONE ANTENNA ELEMENT OPERABLE AT MULTIPLE FREQUENCIES PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA 2011-10-20 — — US disclosed
US-20110253559-A1 Hat storing container MCDONALD LAMARCUS 2011-10-20 — — US disclosed
EP-2377470-A1 Tapered looped suture Tyco Healthcare Group LP (US) 2011-10-19 — — EP disclosed
US-8041772-B2 Autonomic sensor network ecosystem INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2011-10-18 — — US disclosed
EP-2374416-A2 Deployment system for surgical suture Tyco Healthcare Group LP (US) 2011-10-12 — — EP disclosed
US-20110232838-A1 Therapeutic Implant COVIDIEN LP 2011-09-29 — — US disclosed
US-20110236459-A1 Therapeutic Implant COVIDIEN LP 2011-09-29 — — US disclosed
US-20110236460-A1 Therapeutic Implant COVIDIEN LP 2011-09-29 — — US disclosed
EP-2368523-A1 Therapeutic Implant Tyco Healthcare Group LP (US) 2011-09-28 — — EP disclosed
EP-2368522-A1 Therapeutic implant Tyco Healthcare Group LP (US) 2011-09-28 — — EP disclosed
EP-2368501-A1 Knotted suture end effector Tyco Healthcare Group LP (US) 2011-09-28 — — EP disclosed
EP-2368521-A1 Therapeutic implant Tyco Healthcare Group LP (US) 2011-09-28 — — EP disclosed
WO-2011103555-A2 MINIMALLY-INVASIVE METHOD AND APPARATUS FOR RESTRUCTURING THE RETINA MAZZOCCHI RUDY A (US) 2011-08-25 — — WO disclosed
CN-101404984-B Powder filling processes 3M INNOVATIVE PROPERTIES CO 2011-07-06 — — CN disclosed
US-7960439-B1 Environmentally sensitive foldable oligomers IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2011-06-14 — — US disclosed
US-20110129533-A1 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE, INC. 2011-06-02 — — US disclosed
US-20110123614-A1 Oral Dosage Forms for Delivery of Therapeutic Agents TYCO HEALTHCARE GROUP (US) 2011-05-26 — — US disclosed
EP-2324822-A2 Oral dosage forms for delivery of therapeutic agents comprising a mechnical fastener Tyco Healthcare Group LP (US) 2011-05-25 — — EP disclosed
US-20110112123-A1 Compositions for Intratumoral Administration TYCO HEALTHCARE GROUP LP (US) 2011-05-12 — — US disclosed
EP-2319506-A1 Compositions for intratumoral administration Tyco Healthcare Group LP (US) 2011-05-11 — — EP disclosed
US-20110091549-A1 Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels CONFLUENT SURGICAL, INC. 2011-04-21 — — US disclosed
US-7919119-B2 Dissolving water insoluble drug in volatility solvent ACUSPHERE, INC. (US) 2011-04-05 — — US disclosed
US-20110064794-A1 Drug Delivery System, its Preparation Process and Use SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-03-17 — — US disclosed
EP-2288340-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF Abraxis BioScience, LLC (US) 2011-03-02 — — EP disclosed
EP-2286798-A1 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof Abraxis BioScience, LLC (US) 2011-02-23 — — EP disclosed
US-20110021643-A1 PROCESSED STARCH POWDER WITH EXCELLENT DISINTEGRATION PROPERTIES AND MANUFACTURING METHOD THEREOF ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-01-27 — — US disclosed
EP-2272504-A2 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof Abraxis BioScience, LLC (US) 2011-01-12 — — EP disclosed
US-7862807-B2 Dendrimers as molecular translocators UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) 2011-01-04 — — US disclosed
EP-2261263-A1 PROCESSED STARCH POWDER WITH EXCELLENT DISINTEGRATION PROPERTIES AND MANUFACTURING METHOD THEREOF Asahi Kasei Chemicals Corporation (JP) 2010-12-15 — — EP disclosed
WO-2010135253-A2 DRY POWDER INHALER DOSE COUNTERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-11-25 — — WO disclosed
WO-2010135340-A2 DRY POWDER INHALERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-11-25 — — WO disclosed
US-7829114-B2 Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin CYDEX PHARMACEUTICALS, INC. (US) 2010-11-09 — — US disclosed
US-20100278725-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING LIU, JIANG, DR. (CA) 2010-11-04 — — US disclosed
US-20100274283-A1 ANCHORING DEVICE COVIDIEN LP 2010-10-28 — — US disclosed
EP-2243495-A1 A DRUG DELIVERY SYSTEM, ITS PREPARATION PROCESS AND USE Shenyang Pharmaceutical University (CN) 2010-10-27 — — EP disclosed
WO-2010120892-A2 IMPROVED ORAL DRUG DEVICES AND DRUG FORMULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-21 — — WO disclosed
US-20100268272-A1 ANCHORING DEVICE COVIDIEN LP 2010-10-21 — — US disclosed
WO-2010118365-A1 NANOPARTICLE FORMULATIONS AND USES THEROF ABRAXIS BIOSCIENCE, LLC (US) 2010-10-14 — — WO disclosed
US-20100249802-A1 Soft Tissue Graft Preparation Devices and Methods COVIDIEN LP 2010-09-30 — — US disclosed
EP-2233080-A1 Soft tissue graft preparation devices and methods Tyco Healthcare Group LP (US) 2010-09-29 — — EP disclosed
US-20100229859-A1 POWDER FILLING PROCESSES 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-09-16 — — US disclosed
US-20100228270-A1 Deployment System for Surgical Suture COVIDIEN LP 2010-09-09 — — US disclosed
US-20100204730-A1 Knotted Suture End Effector COVIDIEN LP 2010-08-12 — — US disclosed
US-20100199983-A1 METERED DOSE VALVES AND DISPENSERS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2010-08-12 — — US disclosed
US-20100204729-A1 Tapered Looped Suture COVIDIEN LP 2010-08-12 — — US disclosed
US-20100151036-A1 Multiphase drug delivery system WU BIN 2010-06-17 — — US disclosed
US-20100035800-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF AMERICAN BIOSCIENCE, INC. 2010-02-11 — — US disclosed
US-20100018524-A1 METERED DOSE DISPENSERS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2010-01-28 — — US disclosed
US-20100015195-A1 INJECTABLE DEPOT COMPOSITIONS AND IT'S PROCESS OF PREPARATION PANACEA BIOTEC LTD. (IN) 2010-01-21 — — US disclosed
US-20090311249-A1 Capecitabine Combination Therapy ARIAD PHARMACEUTICALS, INC. 2009-12-17 — — US disclosed
US-20090304787-A1 DRUG DELIVERY COMPOSITION ODIDI ISA 2009-12-10 — — US disclosed
US-20090269401-A1 Controlled Release Solid Preparation ASAHI KASEI CHEMICALS CORPORATION (JP) 2009-10-29 — — US disclosed
US-20090263476-A1 Composition of Rapid Disintegrating Direct Compression Buccal Tablet PROVIDENT BANK 2009-10-22 — — US disclosed
US-20090263483-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2009-10-22 — — US disclosed
WO-2009126938-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCES, LLC (US) 2009-10-15 — — WO disclosed
EP-1973527-B1 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PARENTERAL ADMINISTRATION ACUSPHERE INC (US) 2009-10-07 — — EP disclosed
US-20090220613-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT 1001112561 ONTARIO INC. (CA) 2009-09-03 — — US disclosed
EP-2089000-A2 INJECTABLE DEPOT COMPOSITION AND ITS PROCESS OF PREPARATION Panacea Biotec Ltd. (IN) 2009-08-19 — — EP disclosed
EP-2073876-A1 METERED DOSE VALVES AND DISPENSERS 3M Innovative Properties Company (US) 2009-07-01 — — EP disclosed
EP-1180020-B2 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE INC (US) 2009-06-24 — — EP disclosed
EP-2043718-A1 METERED DOSE DISPENSERS 3M Innovative Properties Company (US) 2009-04-08 — — EP disclosed
EP-0961612-B1 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS AND THEIR USE ABRAXIS BIOSCIENCE LLC (US) 2009-04-08 — — EP disclosed
CN-101404984-A Powder filling processes 3M INNOVATIVE PROPERTIES CO (US) 2009-04-08 — — CN disclosed
EP-2032168-A1 CAPECITABINE COMBINATION THERAPY ARIAD GENE THERAPEUTICS, INC. (US) 2009-03-11 — — EP disclosed
EP-2010162-A1 DRUG DELIVERY COMPOSITION Odidi, Isa (CA) 2009-01-07 — — EP disclosed
EP-2007360-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT Odidi, Isa (CA) 2008-12-31 — — EP disclosed
EP-1996173-A2 POWDER FILLING PROCESSES 3M Innovative Properties Company (US) 2008-12-03 — — EP disclosed
CN-101304764-A Solid formulation to control elution of active ingredient to sustained-release ASAHI CHEMICAL CORP (JP) 2008-11-12 — — CN disclosed
EP-1981479-A1 VITAMIN E SUCCINATE STABILIZED PHARMACEUTICAL COMPOSITIONS, METHODS FOR THE PREPARATION AND THE USE THEREOF SD Pharmaceuticals, Inc. (US) 2008-10-22 — — EP disclosed
EP-1978933-A2 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION Acusphere, Inc. (US) 2008-10-15 — — EP disclosed
US-20080249191-A1 SOLUBILIZING COMPOSITION NOF CORPORATION (JP) 2008-10-09 — — US disclosed
EP-1973523-A2 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PULMONARY OR NASAL ADMINISTRATION Acusphere, Inc. (US) 2008-10-01 — — EP disclosed
EP-1973527-A2 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PARENTERAL ADMINISTRATION Acusphere, Inc. (US) 2008-10-01 — — EP disclosed
US-20080221020-A1 Dendrimers as Molecular Translocators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-11 — — US disclosed
US-20080213370-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. 2008-09-04 — — US disclosed
EP-1959924-A2 COMPOSITION OF FENTANYL CITRATE ORAL SOLID TRANSMUCOSAL DOSAGE FORM, DEXTROSE MONOHYDRATE AS MAJOR EXCIPIENT AND BINDING MATERIAL THEREFOR AND METHODS OF PRODUCING THEM Navinta, llc. (US) 2008-08-27 — — EP disclosed
EP-1946780-A1 CONTROLLED RELEASE SOLID PREPARATION Asahi Kasei Chemicals Corporation (JP) 2008-07-23 — — EP disclosed
EP-1944019-A2 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof Abraxis BioScience, Inc. (US) 2008-07-16 — — EP disclosed
US-20080160095-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, LLC (US) 2008-07-03 — — US disclosed
US-20080161382-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof AMERICAN BIOSCIENCE, INC. 2008-07-03 — — US disclosed
US-20080119421-A1 Process for treating a biological organism TECHNOLOGY INNOVATIONS, LLC 2008-05-22 — — US disclosed
EP-1922094-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING University Health Network (CA) 2008-05-21 — — EP disclosed
WO-2008049107-A1 METERED DOSE VALVES AND DISPENSERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-04-24 — — WO disclosed
WO-2008041245-A2 INJECTABLE DEPOT COMPOSITION AND IT'S PROCESS OF PREPARATION PANACEA BIOTEC LTD. (IN) 2008-04-10 — — WO disclosed
US-7351421-B2 Drug-eluting stent having collagen drug carrier chemically treated with genipin GP MEDICAL, INC. 2008-04-01 — — US disclosed
US-20080045584-A1 Use of Docetaxel for Treating Hepatocellular Carcinoma AVENTIS PHARMA S.A. (FR) 2008-02-21 — — US disclosed
WO-2008014161-A1 METERED DOSE DISPENSERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-01-31 — — WO disclosed
EP-1877040-A1 EXTENDED RELEASE FORMULATIONS Teva Pharmaceuticals USA, Inc. (US) 2008-01-16 — — EP disclosed
EP-1545505-A4 DRUG-LOADED BIOLOGICAL MATERIAL CHEMICALLY TREATED WITH GENIPIN GP MEDICAL (US) 2008-01-02 — — EP disclosed
CN-101094646-A Low oil emulsion compositions for delivering taxoids and other insoluble drugs XIAN CHEN ANDREW (US) 2007-12-26 — — CN disclosed
WO-2007143212-A1 CAPECITABINE COMBINATION THERAPY ARIAD GENE THERAPEUTICS, INC. (US) 2007-12-13 — — WO disclosed
EP-1414497-A4 NOVEL MICROEMULSION AND MICELLE SYSTEMS FOR SOLUBILIZING DRUGS UNIV FLORIDA (US) 2007-11-21 — — EP disclosed
US-20070264343-A1 METHODS FOR MAKING AND USING PARTICULATE PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE ACUSPHERE, INC. (US) 2007-11-15 — — US disclosed
US-7282220-B1 Genipin-crosslinked gelatin microspheres as drug carrier GP MEDICAL 2007-10-16 — — US disclosed
WO-2007112581-A1 CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT ODIDI ISA (CA) 2007-10-11 — — WO disclosed
WO-2007112579-A1 DRUG DELIVERY COMPOSITION ODIDI ISA (CA) 2007-10-11 — — WO disclosed
WO-2007112267-A2 POWDER FILLING PROCESSES 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-04 — — WO disclosed
EP-1831389-A1 METHOD FOR BIOTRANSFORMATION OF THE CLYCLOSPORIN COMPOUND ISA247 Isotechnika Inc. (CA) 2007-09-12 — — EP disclosed
US-20070207173-A1 Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof SD PHARMACEUTICALS, INC. (US) 2007-09-06 — — US disclosed
US-20070196361-A1 Long term administration of pharmacologically active agents ABRAXIS BIOSCIENCE, LLC 2007-08-23 — — US disclosed
US-20070196914-A1 Methods for preparing oil bodies comprising active ingredients SEMBIOSYS GENETICS INC. (CA) 2007-08-23 — — US disclosed
US-20070191473-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof AMERICAN BIOSCIENCE, INC. 2007-08-16 — — US disclosed
WO-2007089931-A1 VITAMIN E SUCCINATE STABILIZED PHARMACEUTICAL COMPOSITIONS, METHODS FOR THE PREPARATION AND THE USE THEREOF SD PHARMACEUTICALS, INC. (US) 2007-08-09 — — WO disclosed
EP-1545462-A4 DENDRIMERS AS MOLECULAR TRANSLOCATORS UNIV CALIFORNIA (US) 2007-08-08 — — EP disclosed
WO-2007086882-A2 BIOLOGICAL POLYMER WITH DIFFERENTLY CHARGED PORTIONS TECHNOLOGY INNOVATIONS, LLC (US) 2007-08-02 — — WO disclosed
US-20070178166-A1 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PULMONARY OR NASAL ADMINISTRATION ACUSPHERE, INC. (US) 2007-08-02 — — US disclosed
US-20070178165-A1 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PARENTERAL ADMINISTRATION ACUSPHERE, INC. (US) 2007-08-02 — — US disclosed
EP-1804765-A2 LOW OIL EMULSION COMPOSITIONS FOR DELIVERING TAXOIDS AND OTHER INSOLUBLE DRUGS SD Pharmaceuticals, Inc. (US) 2007-07-11 — — EP disclosed
US-20070149496-A1 Water-soluble compound TECHNOLOGY INNOVATIONS, LLC 2007-06-28 — — US disclosed
US-20070148211-A1 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION ACUSPHERE, INC. (US) 2007-06-28 — — US disclosed
WO-2007070852-A2 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PARENTERAL ADMINISTRATION ACUSPHERE, INC. (US) 2007-06-21 — — WO disclosed
WO-2007070851-A2 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PULMONARY OR NASAL ADMINISTRATION ACUSPHERE, INC. (US) 2007-06-21 — — WO disclosed
WO-2007070843-A2 PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION ACUSPHERE, INC. (US) 2007-06-21 — — WO disclosed
US-20070141100-A1 Drug-eluting biodegradable stent GP MEDICAL, INC. 2007-06-21 — — US disclosed
US-20070128290-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. (US) 2007-06-07 — — US disclosed
US-20070122465-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. 2007-05-31 — — US disclosed
US-20070122468-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. 2007-05-31 — — US disclosed
WO-2007058923-A2 COMPOSITION OF FENTANYL CITRATE ORAL SOLID TRANSMUCOSAL DOSAGE FORM, DEXTROSE MONOHYDRATE AS MAJOR EXCIPIENT AND BINDING MATERIAL THEREFOR AND METHODS OF PRODUCING THEM NAVINTA LLC (US) 2007-05-24 — — WO disclosed
US-20070117863-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof AMERICAN BIOSCIENCE, INC. 2007-05-24 — — US disclosed
US-20070116761-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. 2007-05-24 — — US disclosed
US-20070117862-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. 2007-05-24 — — US disclosed
US-20070104763-A1 Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making NAVINTA LLC 2007-05-10 — — US disclosed
WO-2007050135-A2 PROCESS FOR TREATING A BIOLOGICAL ORGANISM TECHNOLOGY INNOVATIONS, LLC (US) 2007-05-03 — — WO disclosed
US-20070092563-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. (US) 2007-04-26 — — US disclosed
US-20070092549-A1 Water-soluble compound TECHNOLOGY INNOVATIONS LLC 2007-04-26 — — US disclosed
US-20070093547-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, LLC 2007-04-26 — — US disclosed
US-20070087022-A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof ABRAXIS BIOSCIENCE, INC. (US) 2007-04-19 — — US disclosed
WO-2007019678-A1 METHODS AND DEVICES FOR LYMPHATIC TARGETING UNIVERSITY HEALTH NETWORK (CA) 2007-02-22 — — WO disclosed
US-20070027129-A1 Water-soluble compound TECHNOLOGY INNOVATIONS LLC 2007-02-01 — — US disclosed
US-20070010702-A1 Medical device with low magnetic susceptibility BIOPHAN TECHNOLOGIES, INC. 2007-01-11 — — US disclosed
EP-1734926-A2 AQUEOUS SOLUTIONS COMPRISING PREDNISOLONE AND A CYCLODEXTRIN DERIVATIVE Allergan, Inc. (US) 2006-12-27 — — EP disclosed
US-20060275367-A1 Extended release formulations TEVA PHARMACEUTICALS USA, INC. 2006-12-07 — — US disclosed
EP-1545477-A4 CAPSULES CONTAINING AQUEOUS FILL COMPOSITIONS STABILIZED WITH DERIVATIZED CYCLODEXTRIN CYDEX INC (US) 2006-11-22 — — EP disclosed
WO-2006121447-A2 THERAPEUTIC ASSEMBLY NANOSET, LLC (US) 2006-11-16 — — WO disclosed
US-20060258617-A1 DRUG DELIVERY TO THE BACK OF THE EYE ALLERGAN, INC. 2006-11-16 — — US disclosed
CN-1863506-A Methods for preparing oil bodies comprising active ingredients SEMBIOSYS GENETICS INC (CA) 2006-11-15 — — CN disclosed
WO-2006116247-A1 EXTENDED RELEASE FORMULATIONS TEVA PHARMACEUTICALS USA, INC. (US) 2006-11-02 — — WO disclosed
CN-1856296-A Injectable, oral, or topical sustained release pharmaceutical formulations ACUSPHERE INC (US) 2006-11-01 — — CN disclosed
WO-2006104510-A2 WATER-SOLUBLE COMPOUND TECHNOLOGY INNOVATIONS, LLC (US) 2006-10-05 — — WO disclosed
US-20060216265-A1 Dendrimers as molecular translocators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2006-09-28 — — US disclosed
US-7101857-B2 Crosslinkable biological material and medical uses GP MEDICAL, INC. (US) 2006-09-05 — — US disclosed
EP-1023050-A4 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF AMERICAN BIOSCIENCE INC (US) 2006-08-30 — — EP disclosed
EP-1689322-A1 DRUG-ELUTING BIODEGRADABLE STENT GP Medical, Inc. (US) 2006-08-16 — — EP disclosed
US-20060177480-A1 Drug-eluting biodegradable stent GP MEDICAL, INC. 2006-08-10 — — US disclosed
EP-1685835-A2 Long term administration of sub-therapeutic dose levels of pharmacologically active agents American Bioscience, Inc. (US) 2006-08-02 — — EP disclosed
EP-1587524-A4 COMPOSITIONS AND METHODS FOR TARGETED BIOLOGICAL DELIVERY OF MOLECULAR CARRIERS ARIZEKE PHARMACEUTICALS INC (US) 2006-07-26 — — EP disclosed
US-7074821-B1 Taxoids, their preparation and pharmaceutical composition containing them AVENTIS PHARMA, S.A. (FR) 2006-07-11 — — US disclosed
US-20060147371-A1 Water-soluble compound TECHNOLOGY INNOVATIONS, LLC 2006-07-06 — — US disclosed
WO-2006066416-A1 METHOD FOR BIOTRANSFORMATION OF THE CLYCLOSPORIN COMPOUND ISA247 ISOTECHNIKA INC. (CA) 2006-06-29 — — WO disclosed
EP-1670434-A1 METHODS FOR PREPARING OIL BODIES COMPRISING ACTIVE INGREDIENTS SemBioSys Genetics Inc. (CA) 2006-06-21 — — EP disclosed
EP-1667659-A1 INJECTABLE, ORAL, OR TOPICAL SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS Acusphere, Inc. (US) 2006-06-14 — — EP disclosed
US-20060100578-A1 Medication delivery apparatus and methods for intravenous infusions TANDEM MEDICAL, INC. 2006-05-11 — — US disclosed
WO-2006049812-A2 PROCESS FOR TREATING A BIOLOGICAL ORGANISM TECHNOLOGY INNOVATIONS, LLC (US) 2006-05-11 — — WO disclosed
US-20060093678-A1 Methods for making pharmaceutical formulations comprising deagglomerated microparticles CEPHALON, INC. 2006-05-04 — — US disclosed
US-20060093677-A1 Methods for making pharmaceutical formulations comprising deagglomerated microparticles CEPHALON, INC. 2006-05-04 — — US disclosed
US-7025059-B2 Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract LLOYDS INTERNATIONAL CREDIT, LLC 2006-04-11 — — US disclosed
WO-2006037089-A2 LOW OIL EMULSION COMPOSITIONS FOR DELIVERING TAXOIDS AND OTHER INSOLUBLE DRUGS SD PHARMACEUTICALS, INC. (US) 2006-04-06 — — WO disclosed
EP-1642572-A1 Porous drug matrices and methods of manufacture thereof Acusphere, Inc. (US) 2006-04-05 — — EP disclosed
US-20060067952-A1 Low oil emulsion compositions for delivering taxoids and other insoluble drugs SD PHARMACEUTICALS, INC. (US) 2006-03-30 — — US disclosed
WO-2006023261-A2 MEDICAL DEVICE WITH MULTIPLE COATING LAYERS NANOSET, LLC (US) 2006-03-02 — — WO disclosed
EP-1178786-A4 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF AMERICAN BIOSCIENCE INC (US) 2006-03-01 — — EP disclosed
US-20060039976-A1 Controlled release composition using transition coating, and method of preparing same INTELLIPHARMACEUTICS CORP (CA) 2006-02-23 — — US disclosed
US-20060034943-A1 Process for treating a biological organism TECHNOLOGY INNOVATIONS LLC 2006-02-16 — — US disclosed
US-20060034885-A1 Medical use of aglycon geniposidic acid GP MEDICAL, INC. 2006-02-16 — — US disclosed
US-20060024361-A1 Disintegrant assisted controlled release technology INTELLIPHARMACEUTICS CORP (CA) 2006-02-02 — — US disclosed
WO-2006007359-A1 ANTI-MITOTIC COMPOUND TECHNOLOGY INNOVATIONS, LLC (US) 2006-01-19 — — WO disclosed
EP-0961612-A4 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF AMERICAN BIOSCIENCE INC (US) 2005-12-21 — — EP disclosed
EP-1180020-B1 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE INC (US) 2005-12-14 — — EP disclosed
WO-2005110285-A2 VARIABLE WALL ENDOVASCULAR STENT GMP/CARDIAC CARE, INC. (US) 2005-11-24 — — WO disclosed
US-20050249721-A1 Compositions and methods for targeted biological delivery of molecular carriers ARIZEKE PHARMACEUTICALS, INC. 2005-11-10 — — US disclosed
US-20050249667-A1 Process for treating a biological organism TECHNOLOGY INNOVATIONS, LLC 2005-11-10 — — US disclosed
WO-2005105067-A2 AQUEOUS SOLUTIONS COMPRISING PREDNISOLONE AND A CYCLODEXTRIN DERIVATIVE ALLERGAN, INC. (US) 2005-11-10 — — WO disclosed
US-20050238616-A1 Compositions for treatment of central nervous system neoplasms, and methods of making and using the same GUILFORD PHARMACEUTICALS, INC. (US) 2005-10-27 — — US disclosed
EP-1587524-A2 COMPOSITIONS AND METHODS FOR TARGETED BIOLOGICAL DELIVERY OF MOLECULAR CARRIERS ARIZEKE PHARMACEUTICALS, INC. (US) 2005-10-26 — — EP disclosed
US-20050234018-A1 Drug delivery to the back of the eye ALLERGAN, INC. (US) 2005-10-20 — — US disclosed
US-20050215764-A1 Biological polymer with differently charged portions TECHNOLOGY INNOVATIONS, LLC 2005-09-29 — — US disclosed
EP-1575560-A2 METHODS FOR MAKING PHARMACEUTICAL FORMULATIONS COMPRISING DEAGGLOMERATED MICROPARTICLES Acusphere, Inc. (US) 2005-09-21 — — EP disclosed
WO-2005079301-A2 VENA CAVA RAIL FILTER GMP CARDIAC CARE, INC. (US) 2005-09-01 — — WO disclosed
EP-1567221-A1 RAIL STENT GMP Cardiac Care, Inc. (US) 2005-08-31 — — EP disclosed
US-20050186267-A1 Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2005-08-25 — — US disclosed
US-6932983-B1 Porous drug matrices and methods of manufacture thereof ACUSPHERE, INC. (US) 2005-08-23 — — US disclosed
US-20050171616-A1 Peritoneal regeneration with acellular pericardial patch GP MEDICAL, INC. 2005-08-04 — — US disclosed
US-20050163818-A1 delivering medical equipment having layers or zones containing drugs, to the target tissues for release of drugs; tissue-targeted therapy; drug delivery GP MEDICAL 2005-07-28 — — US disclosed
US-20050163821-A1 Drug-eluting Biodegradable Stent and Delivery Means GP MEDICAL, INC. 2005-07-28 — — US disclosed
EP-1556018-A1 SUSTAINED RELEASE POROUS MICROPARTICLES FOR INHALATION Acusphere, Inc. (US) 2005-07-27 — — EP disclosed
EP-1545477-A1 CAPSULES CONTAINING AQUEOUS FILL COMPOSITIONS STABILIZED WITH DERIVATIZED CYCLODEXTRIN Cydex Inc. (US) 2005-06-29 — — EP disclosed
EP-1545462-A2 DENDRIMERS AS MOLECULAR TRANSLOCATORS The Regents of the University of California (US) 2005-06-29 — — EP disclosed
EP-1545505-A2 DRUG-LOADED BIOLOGICAL MATERIAL CHEMICALLY TREATED WITH GENIPIN GP Medical (US) 2005-06-29 — — EP disclosed
EP-1162952-A4 CYTOPROTECTIVE BIOCOMPATIBLE CONTAINMENT SYSTEMS FOR BIOLOGICALLY ACTIVE MATERIALS AND METHODS OF MAKING SAME VIVORX INC (US) 2005-06-15 — — EP disclosed
US-20050123582-A1 Drug-eluting stent having collagen drug carrier chemically treated with genipin GP MEDICAL, INC. 2005-06-09 — — US disclosed
US-20050124560-A1 Administrering a biological patch, cardiac tissue anti-adhesion membrane or myocardial tissue loaded with an angiogenesis factor of ginsenosides; substrate is crosslinked with genepin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimide, carbodiimides GP MEDICAL, INC. 2005-06-09 — — US disclosed
WO-2005046519-A1 DRUG-ELUTING BIODEGRADABLE STENT GP MEDICAL, INC. (US) 2005-05-26 — — WO disclosed
US-20050107870-A1 Medical device with multiple coating layers BIOPHAN TECHNOLOGIES, INC. 2005-05-19 — — US disclosed
US-20050095197-A1 Anti-mitotic compound TECHNOLOGY INNOVATIONS LLC 2005-05-05 — — US disclosed
WO-2005032523-A1 INJECTABLE, ORAL, OR TOPICAL SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS ACUSPHERE, INC. (US) 2005-04-14 — — WO disclosed
US-20050079132-A1 Medical device with low magnetic susceptibility BIOPHAN TECHNOLOGIES, INC. 2005-04-14 — — US disclosed
US-20050079138-A1 Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability CEPHALON, INC. 2005-04-14 — — US disclosed
WO-2005030169-A1 METHODS FOR PREPARING OIL BODIES COMPRISING ACTIVE INGREDIENTS SEMBIOSYS GENETICS INC. (CA) 2005-04-07 — — WO disclosed
US-20050069591-A1 Injectable, oral, or topical sustained release pharmaceutical formulations CEPHALON, INC. 2005-03-31 — — US disclosed
US-20050058710-A1 Porous drug matrices and methods of manufacture thereof ACUSPHERE, INC. 2005-03-17 — — US disclosed
US-20050048116-A1 Porous drug matrices and methods of manufacture thereof BURRILL LIFE SCIENCES CAPITAL FUND III, L.P. 2005-03-03 — — US disclosed
WO-2005011752-A1 METHOD OF STERILIZATION BY IRRADIATION OF POLYMERIC MATERIALS SUITABLE FOR THERAPEUTICAL PURPOSES ALLERGAN, INC. (US) 2005-02-10 — — WO disclosed
US-20050025797-A1 Medical device with low magnetic susceptibility BIOPHAN TECHNOLOGIES, INC. 2005-02-03 — — US disclosed
US-20050019404-A1 delivering medical equipment having layers or zones containing drugs, to the target tissues for release of drugs; tissue-targeted therapy; drug delivery GP MEDICAL, INC. 2005-01-27 — — US disclosed
US-20050003007-A1 Method of sterilization of polymeric microparticles ALLERGAN, INC 2005-01-06 — — US disclosed
US-20040255940-A1 Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract LLOYDS INTERNATIONAL CREDIT, LLC 2004-12-23 — — US disclosed
US-20040254419-A1 Therapeutic assembly BIOPHAN TECHNOLOGIES, INC. 2004-12-16 — — US disclosed
CN-1174748-C New use of docetaxel for treating hepatoma ���ĵ�˹ҩ��ɷ����޹�˾ 2004-11-10 — — CN disclosed
US-20040198813-A1 Novel microemulsion and micelle systems for solubilizing drugs UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2004-10-07 — — US disclosed
US-20040157330-A1 Compositions and methods for targeted biological delivery of molecular carriers ARIZEKE PHARMACEUTICALS, INC. 2004-08-12 — — US disclosed
WO-2004062602-A2 COMPOSITIONS AND METHODS FOR TARGETED BIOLOGICAL DELIVERY OF MOLECULAR CARRIERS ARIZEKE PHARMACEUTICALS INC. (US) 2004-07-29 — — WO disclosed
WO-2004060344-A2 METHODS FOR MAKING PHARMACEUTICAL FORMULATIONS COMPRISING DEAGGLOMERATED MICROPARTICLES ACUSPHERE, INC. (US) 2004-07-22 — — WO disclosed
US-20040121003-A1 Methods for making pharmaceutical formulations comprising deagglomerated microparticles ACUSPHERE, INC. (US) 2004-06-24 — — US disclosed
EP-1214061-B1 USE OF DOCETAXEL FOR TREATING HEPATOCELLULAR CARCINOMA AVENTIS PHARMA SA (FR) 2004-06-23 — — EP disclosed
US-6749868-B1 DISPERSIBLE COLLOIDAL SYSTEMS CONTAINING WATER INSOLUBLE PHARMACOLOGICALLY ACTIVE AGENTS AMERICAN BIOSCIENCE, INC. 2004-06-15 — — US disclosed
US-20040106975-A1 Rail stent GMP/CARDIAC CARE, INC. 2004-06-03 — — US disclosed
US-20040105821-A1 Sustained release pharmaceutical formulation for inhalation CEPHALON, INC. 2004-06-03 — — US disclosed
WO-2004045474-A1 RAIL STENT GMP CARDIAC CARE, INC. (US) 2004-06-03 — — WO disclosed
EP-1414497-A1 NOVEL MICROEMULSION AND MICELLE SYSTEMS FOR SOLUBILIZING DRUGS UNIVERSITY OF FLORIDA (US) 2004-05-06 — — EP disclosed
WO-2004030659-A1 SUSTAINED RELEASE POROUS MICROPARTICLES FOR INHALATION ACUSPHERE, INC. (US) 2004-04-15 — — WO disclosed
WO-2004024126-A1 CAPSULES CONTAINING AQUEOUS FILL COMPOSITIONS STABILIZED WITH DERIVATIZED CYCLODEXTRIN CYDEX, INC. (US) 2004-03-25 — — WO disclosed
US-6710086-B1 CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT MEDINOX, INC. 2004-03-23 — — US disclosed
WO-2004012676-A2 DRUG-LOADED BIOLOGICAL MATERIAL CHEMICALLY TREATED WITH GENIPIN GP MEDICAL (US) 2004-02-12 — — WO disclosed
WO-2004009665-A2 DENDRIMERS AS MOLECULAR TRANSLOCATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-01-29 — — WO disclosed
WO-2004009666-A2 DENDRIMERS AS MOLECULAR TRANSLOCATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-01-29 — — WO disclosed
US-6667313-B1 High affinity and specificity LIGAND PHARMACEUTICALS INC. 2003-12-23 — — US disclosed
US-6667410-B2 Reducing an alpha-beta-unsaturated ketone to an alpha-hydroxyketone in presence of a catalyst containing manganes complex and a reducing agent BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-12-23 — — US disclosed
EP-1368328-A1 METHODS FOR PREPARING NEW TAXOIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Aventis Pharma S.A. (FR) 2003-12-10 — — EP disclosed
US-6645528-B1 Rate of dissolution of drugs can be enhanced by making the drug into a porous matrix form ACUSPHERE, INC. 2003-11-11 — — US disclosed
US-6641831-B1 Nondegradable; monolithic distribution of substances having different hydrophilicity dispersed in polymeric matrix SCHIERHOLZ JOERG (DE) 2003-11-04 — — US disclosed
US-6638537-B2 Microemulsion and micelle systems for solubilizing drugs UNIVERSITY OF FLORIDA 2003-10-28 — — US disclosed
WO-2003084470-A2 COMPOSITIONS AND METHODS FOR TARGETED BIOLOGICAL DELIVERY OF MOLECULAR CARRIERS ARIZEKE PHARMACEUTICALS, INC. (US) 2003-10-16 — — WO disclosed
US-20030191071-A1 DRUG-LOADED BIOLOGICAL MATERIAL CHEMICALLY TREATED WITH GENIPIN GP MEDICAL 2003-10-09 — — US disclosed
US-6623765-B1 Long chain polymer surfactant and short fatty acid surfactant UNIVERSITY OF FLORIDA, RESEARCH FOUNDATION, INCORPORATED 2003-09-23 — — US disclosed
US-6624138-B1 Drug-loaded biological material chemically treated with genipin GP MEDICAL 2003-09-23 — — US disclosed
US-20030158249-A1 Use of docetaxel for treating hepatoma AVENTIS PHARMA S.A. 2003-08-21 — — US disclosed
US-20030149268-A1 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators HAMANN LAWRENCE G (US) 2003-08-07 — — US disclosed
WO-2003060799-A2 COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM NEOPLASMS, AND METHODS OF MAKING AND USING THE SAME GUILFORD PHARMACEUTICALS, INC. (US) 2003-07-24 — — WO disclosed
US-20030133903-A1 Compositions for treatment of prostate cancers and methods of making and using the same GUILFORD PHARMACEUTICALS, INC. 2003-07-17 — — US disclosed
US-20030134892-A1 Compositions for treatment of head and neck cancers, and methods of making and using the same GUILFORD PHARMACEUTICALS, INC. 2003-07-17 — — US disclosed
US-6593482-B2 (2R,3S)-3-benzoyl-2-hydroxy-3-phenylpropionate of 4,10-beta-diacetoxy-2 alpha-benzoyloxy-5 beta ,20-epoxy-1,13-alpha-dihydroxy-7-beta-methylthiomethyloxy-9-oxo-tax-11-ene from baccatin and beta-lactam AVENTIS PHARMA S.A. (FR) 2003-07-15 — — US disclosed
US-20030130645-A1 Devices and methods for delivery of medically appropriate fluids TANDEM MEDICAL, INC. 2003-07-10 — — US disclosed
WO-2003047649-A2 DEVICES AND METHODS FOR DELIVERY OF MEDICALLY APPROPRIATE FLUIDS TANDEM MEDICAL, INC. (US) 2003-06-12 — — WO disclosed
US-20030087840-A1 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor MEDINOX, INC. 2003-05-08 — — US disclosed
EP-0871357-B1 METHOD FOR DEVELOPMENT OF TRANSGENIC GOATS NEXIA BIOTECH INC (CA) 2003-05-02 — — EP disclosed
EP-1305005-A2 MICROEMULSION AND MICELLE SYSTEMS FOR SOLUBILIZING DRUGS UNIVERSITY OF FLORIDA (US) 2003-05-02 — — EP disclosed
US-20030083497-A1 Taxoids, their preparation and pharmaceutical compositions containing them AVENTIS PHARMA, S.A. 2003-05-01 — — US disclosed
WO-2003015823-A1 NOVEL MICROEMULSION AND MICELLE SYSTEMS FOR SOLUBILIZING DRUGS UNIVERSITY OF FLORIDA (US) 2003-02-27 — — WO disclosed
WO-2003007914-A2 BIOCOMPATIBLE POLYMER CONTAINING COMPOSITION FOR TREATMENT OF PROSTATE CANCERS GUILFORD PHARMACEUTICALS, INC. (US) 2003-01-30 — — WO disclosed
WO-2003007915-A2 COMPOSITIONS FOR TREATMENT OF HEAD AND NECK CANCERS, AND METHODS OF MAKING AND USING THE SAME GUILFORD PHARMACEUTICALS, INC. (US) 2003-01-30 — — WO disclosed
US-6495161-B1 Cytoprotective biocompatible containment systems for biologically active materials and methods of making same VIVORX, INC. 2002-12-17 — — US disclosed
US-20020142050-A1 Porous drug matrices and methods of manufacture thereof ACUSPHERE INC. 2002-10-03 — — US disclosed
CN-1372466-A New use of docetaxel for treating hepatoma AVENTIS PHARMA SA (FR) 2002-10-02 — — CN disclosed
WO-2002070498-A1 METHODS FOR PREPARING NEW TAXOIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA, S.A. (FR) 2002-09-12 — — WO disclosed
US-20020120170-A1 Conversion of alpha,beta-unsaturated ketones and alpha,beta-unsaturated esters into alpha-hydroxy ketones and alpha-hydroxy esters using Mn(III) catalyst, phenylsilane and dioxygen BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM 2002-08-29 — — US disclosed
US-20020120015-A1 Novel microemulsion and micelle systems for solubilizing drugs FLORIDA RESEARCH FOUNDATION, INCORPORATED, UNIVERSITY OF 2002-08-29 — — US disclosed
EP-1171117-A4 LONG TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS AMERICAN BIOSCIENCE INC (US) 2002-08-07 — — EP disclosed
US-20020090399-A1 Cytoprotective biocompatible containment systems for biologically active materials and methods of making same VIVORX, INC. 2002-07-11 — — US disclosed
US-20020087013-A1 Methods for preparing new taxoids and pharmaceutical compositions containing them AVENTIS PHARMA S.A. 2002-07-04 — — US disclosed
EP-1214061-A2 USE OF DOCETAXEL FOR TREATING HEPATOCELLULAR CARCINOMA Aventis Pharma S.A. (FR) 2002-06-19 — — EP disclosed
US-6407135-B1 NITRIC OXIDE SCAVENGER COVALENTLY BONDED TO NON-STEROIDAL ANTIINFLAMMATORY AGENT OR OTHER DRUG; SIDE EFFECT REDUCTION MEDINOX, INC. 2002-06-18 — — US disclosed
EP-1212322-A2 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS LIGAND PHARMACEUTICALS INCORPORATED (US) 2002-06-12 — — EP disclosed
US-6395300-B1 DRUGS HAVING LOW SOLUBILITY, FORMULATIONS OF SUCH DRUGS TO ENHANCE THEIR RATE OF DISSOLUTION ACUSPHERE, INC. 2002-05-28 — — US disclosed
US-6387946-B1 AS ANTITUMOR AND ANTILEUKEMIC AGENTS AVENTIS PHARMA S.A. (FR) 2002-05-14 — — US disclosed
US-6384071-B2 ANTITUMOR AGENTS AVENTIS PHARMA, S.A. (FR) 2002-05-07 — — US disclosed
US-6372780-B2 NEW TAXOIDS PRODUCED BY ESTERIFICATION AT POSITION 13 OF TAXOID RING; ANTITUMOR AND ANTILEUKAEMIC PROPERTIES AVENTIS PHARMA S.A. (FR) 2002-04-16 — — US disclosed
US-20020038038-A1 Methods for treating pathological conditions of abnormal cell proliferation AVENTIS PHARMA S.A. 2002-03-28 — — US disclosed
EP-1180020-A2 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF Acusphere, Inc. (US) 2002-02-20 — — EP disclosed
EP-1178786-A1 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF American Bioscience, Inc. (US) 2002-02-13 — — EP disclosed
WO-2002009671-A2 MICROEMULSION AND MICELLE SYSTEMS FOR SOLUBILIZING DRUGS UNIVERSITY OF FLORIDA (US) 2002-02-07 — — WO disclosed
EP-1176957-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN Aventis Pharma S.A. (FR) 2002-02-06 — — EP disclosed
WO-2000072827-A9 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE INC (US) 2002-01-31 — — WO disclosed
US-20020010348-A1 Methods for preparing new taxoids and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2002-01-24 — — US disclosed
EP-1171117-A1 LONG TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS American Bioscience, Inc. (US) 2002-01-16 — — EP disclosed
EP-1162952-A1 CYTOPROTECTIVE BIOCOMPATIBLE CONTAINMENT SYSTEMS FOR BIOLOGICALLY ACTIVE MATERIALS AND METHODS OF MAKING SAME Vivorx, Inc. (US) 2001-12-19 — — EP disclosed
US-6331635-B1 ANTITUMOR, ANTILEUKEMIA AGENTS AVENTIS PHARMA S.A. (FR) 2001-12-18 — — US disclosed
US-20010051736-A1 New taxoids produced by esterification at position 13 of taxoid ring; antitumor and antileukaemic properties RHONE-POULENC RORER,S.A. 2001-12-13 — — US disclosed
US-20010021783-A1 New taxoids, their preparation and pharmaceutical compositions containing them Rhône-Poulenc Rorer S.A. 2001-09-13 — — US disclosed
WO-2001062085-A1 PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR MEDINOX, INC. (US) 2001-08-30 — — WO disclosed
US-6274627-B1 ADMINISTERING COMPOUNDS SUCH AS N-METHYL-D-GLUCAMINE DITHIO-CARBAMATE DISULFIDE FOR IN VIVO REDUCTION OF FREE RADICAL LEVELS IN A SUBJECT MEDINOX, INC. 2001-08-14 — — US disclosed
US-6232477-B1 SILYLATING A BACCATIN; ACETYLATION; DEBLOCKING AVENTIS PHARMA S.A. (FR) 2001-05-15 — — US disclosed
US-6218406-B1 AS ANTITUMOR AND ANTILEUKEMIC AGENTS AVENTIS PHARMA S.A. (FR) 2001-04-17 — — US disclosed
WO-2001016133-A2 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS LIGAND PHARMACEUTICALS INCORPORATED (US) 2001-03-08 — — WO disclosed
WO-2001015675-A2 USE OF DOCETAXEL FOR TREATING HEPATOCELLULAR CARCINOMA AVENTIS PHARMA S.A. (FR) 2001-03-08 — — WO disclosed
US-6194582-B1 MULTI-DRUG RESISTANCE RHONE-POULENC RORER S.A. (FR) 2001-02-27 — — US disclosed
US-6160135-A Taxoids, preparation thereof and pharmaceutical compositions containing same RHONE-POULENC RORER S.A. (FR) 2000-12-12 — — US disclosed
WO-2000072827-A2 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE, INC. (US) 2000-12-07 — — WO disclosed
US-6156789-A Method for treating abnormal cell proliferation in the brain RHONE-POULENC RORER S.A. (FR) 2000-12-05 — — US disclosed
WO-2000071079-A2 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF AMERICAN BIOSCIENCE, INC. (US) 2000-11-30 — — WO disclosed
WO-2000066113-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN AVENTIS PHARMA S.A. (FR) 2000-11-09 — — WO disclosed
EP-1050302-A1 Method for treating abnormal cell proliferation in the brain Aventis Pharma S.A. (FR) 2000-11-08 — — EP disclosed
WO-2000064437-A1 LONG TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS AMERICAN BIOSCIENCES, INC. (US) 2000-11-02 — — WO disclosed
US-6124465-A Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments RHONE-POULENC S.A. (FR) 2000-09-26 — — US disclosed
WO-2000053159-A1 CYTOPROTECTIVE BIOCOMPATIBLE CONTAINMENT SYSTEMS FOR BIOLOGICALLY ACTIVE MATERIALS AND METHODS OF MAKING SAME VIVORX, INC. (US) 2000-09-14 — — WO disclosed
EP-1023050-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF Vivorx Pharmaceuticals, Inc. (US) 2000-08-02 — — EP disclosed
EP-1001932-A1 CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR Medinox, Inc. (US) 2000-05-24 — — EP disclosed
US-6040466-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE POULENC RORER SA (FR) 2000-03-21 — — US disclosed
US-6013662-A ANTITUMOR, ANTICARCINOGENIC AGENTS RHONE-POULENC RORER S.A. (FR) 2000-01-11 — — US disclosed
EP-0961612-A1 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF Vivorx Pharmaceuticals, Inc. (US) 1999-12-08 — — EP disclosed
US-5968931-A Taxoids, preparation thereof and pharmaceutical compositions containing same RHONE-POULENC RORER S.A. (FR) 1999-10-19 — — US disclosed
US-5959125-A Taxoids, preparation thereof, and pharmaceutical compositions containing same RHONE-POULENC RORER S.A. (FR) 1999-09-28 — — US disclosed
WO-1999040787-A1 MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME MEDINOX, INC. (US) 1999-08-19 — — WO disclosed
WO-1999040907-A1 METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS MEDINOX, INC. (US) 1999-08-19 — — WO disclosed
US-5916910-A Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore MEDINOX, INC. (US) 1999-06-29 — — US disclosed
US-5916596-A WATER INSOLUBLE DRUGS AND DRUG DELIVERY VIVORX PHARMACEUTICALS, INC. (US) 1999-06-29 — — US disclosed
US-5907080-A (A) INTRODUCING A TRANSGENE INTO AN EMBRYO OF A DWARF GOAT, (B) TRANSPLANTING THE EMBRYO INTO A PSEUDOPREGNANT DWARF GOAT, AND (C) ALLOWING THE EMBRYO TO DEVELOP TO TERM. NEXIA BIOTECHNOLOGIES, INC. (CA) 1999-05-25 — — US disclosed
US-5906990-A Taxoids, preparation thereof, and pharmaceutical compositions containing same RHONE-POULENC RORER S.A. (FR) 1999-05-25 — — US disclosed
WO-1999000113-A9 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF VIVORX PHARMACEUTICALS INC (US) 1999-04-08 — — WO disclosed
US-5889043-A Taxoids, preparation thereof and pharmaceutical Compositions containing same RHONE-POULENC RORER S.A. (FR) 1999-03-30 — — US disclosed
US-5875776-A Dry powder inhaler VIVORX PHARMACEUTICALS, INC. (US) 1999-03-02 — — US disclosed
WO-1999000113-A1 NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF VIVORX PHARMACEUTICALS, INC. (US) 1999-01-07 — — WO disclosed
WO-1998055453-A1 CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR MEDINOX, INC. (US) 1998-12-10 — — WO disclosed
US-5847170-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER, S.A. (FR) 1998-12-08 — — US disclosed
US-5840931-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER S.A. (FR) 1998-11-24 — — US disclosed
EP-0871357-A1 METHOD FOR DEVELOPMENT OF TRANSGENIC GOATS Nexia Biotechnologies, Inc. (CA) 1998-10-21 — — EP disclosed
US-5814658-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER S.A. (FR) 1998-09-29 — — US disclosed
US-5777139-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER S.A. (FR) 1998-07-07 — — US disclosed
WO-1998014174-A1 PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF VIVORX PHARMACEUTICALS, INC. (US) 1998-04-09 — — WO disclosed
US-5728849-A ANTITUMOR AND ANTILEUKEMIC AGENTS RHONE-POULENC RORER S.A. (FR) 1998-03-17 — — US disclosed
US-5716994-A PLANT EXTRACTS RHONE-POULENC RORER S.A. (FR) 1998-02-10 — — US disclosed
CN-1170360-A Transdermal delivery system with adhesive overlay and peel seal disc THERATECH INC (US) 1998-01-14 — — CN disclosed
WO-1997045113-A1 NSAIDS FOR REGULATING THE REPRODUCTIVE CYCLE OF DOMESTICATED ANIMALS SEPRACOR INC. (US) 1997-12-04 — — WO disclosed
WO-1997037708-A1 DRY POWDER INHALER VIVORX PHARMACEUTICALS, INC. (US) 1997-10-16 — — WO disclosed
WO-1997019589-A1 METHOD FOR DEVELOPMENT OF TRANSGENIC GOATS NEXIA BIOTECHNOLOGIES, INC. (CA) 1997-06-05 — — WO disclosed
US-5606083-A Process for the preparation of taxane derivatives, new derivatives thus obtained and the compositions which contain them RHONE-POULENC RORER S.A. (FR) 1997-02-25 — — US disclosed
US-5599942-A Taxoid intermediates RHONE-POULENC RORER S.A. (FR) 1997-02-04 — — US disclosed
US-5587493-A Process for preparing taxoids RHONE-POULENC RORER S.A. (FR) 1996-12-24 — — US disclosed
US-5580997-A Baccatin III derivatives RHONE-POULENC RORER S.A. (FR) 1996-12-03 — — US disclosed
US-5580998-A Process for preparing taxoids RHONE-POULENC RORER S.A. (FR) 1996-12-03 — — US disclosed
US-5576450-A Process for preparing taxoids RHONE-POULENC RORER S.A. (FR) 1996-11-19 — — US disclosed
US-5571917-A Taxoid intermediates RHONE-POULENC RORER S.A. (FR) 1996-11-05 — — US disclosed
US-5556877-A ANTITUMOR AGENTS RHONE-POULENC RORER S.A. (FR) 1996-09-17 — — US disclosed
US-5550261-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER S.A. (FR) 1996-08-27 — — US disclosed
US-5532388-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER S.A. (FR) 1996-07-02 — — US disclosed
US-5476954-A Condensing hydroxyl protected taxane derivative with oxazolidine derivative, decyclizing in acid medium, reacting butoxycarbonyl or benzoyl radical with amine, deprotecting, isolating, purifying product RHONE-POULENC RORER S.A. (FR) 1995-12-19 — — US disclosed
US-5476954-A Condensing hydroxyl protected taxane derivative with oxazolidine derivative, decyclizing in acid medium, reacting butoxycarbonyl or benzoyl radical with amine, deprotecting, isolating, purifying product RHONE-POULENC RORER S.A. (FR) 1995-12-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338579-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES RNASE1, RNMT, TRDMT1 ALDH1A1 3715/4885CYP3A4 4885/4885SMN1; SMN2 406/4885
US-20180036419-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY TOP2A, TOP1, TOP2B ALDH1A1 2224/4885CYP3A4 2135/4885SMN1; SMN2 992/4885
US-20050124560-A1 Administrering a biological patch, cardiac tissue anti-adhesion membrane or myocardial tissue loaded with an angiogenesis factor of ginsenosides; substrate is crosslinked with genepin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimide, carbodiimides FABP3, ADM2, RXFP1 ALDH1A1 1605/4885CYP3A4 3903/4885SMN1; SMN2 4831/4885
US-20030158249-A1 Use of docetaxel for treating hepatoma SLC10A1, MTDH, HDGF ALDH1A1 330/4885CYP3A4 1717/4885SMN1; SMN2 4713/4885
US-10653789-B2 Polymer-drug conjugates for combination anticancer therapy TOP2A, TOP1, TOP2B ALDH1A1 2224/4885CYP3A4 2135/4885SMN1; SMN2 992/4885
US-20260078219-A1 Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof HAO2, HRH1, PHB1 ALDH1A1 1430/4885CYP3A4 268/4885SMN1; SMN2 2178/4885
US-20030087840-A1 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor NOS1, PTGS1, NOS2 ALDH1A1 404/4885CYP3A4 1489/4885SMN1; SMN2 4701/4885
US-20050123582-A1 Drug-eluting stent having collagen drug carrier chemically treated with genipin TGFB2, TGFB1, COL14A1 ALDH1A1 3961/4885CYP3A4 3652/4885SMN1; SMN2 2477/4885
US-20200297858-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY TOP2A, TOP1, TOP2B ALDH1A1 2224/4885CYP3A4 2135/4885SMN1; SMN2 992/4885
US-20020038038-A1 Methods for treating pathological conditions of abnormal cell proliferation MKI67, MCL1, ACIN1 ALDH1A1 1034/4885CYP3A4 4087/4885SMN1; SMN2 579/4885
US-20060147371-A1 Water-soluble compound MKI67, CCNI, PCNA ALDH1A1 4736/4885CYP3A4 4611/4885SMN1; SMN2 776/4885
US-11197932-B2 Polymer-drug conjugates for combination anticancer therapy TOP2A, TOP1, TOP2B ALDH1A1 2224/4885CYP3A4 2135/4885SMN1; SMN2 992/4885
US-20210162050-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT CUTA, KRT18, SLC38A7 ALDH1A1 4452/4885CYP3A4 4851/4885SMN1; SMN2 2690/4885
US-20070207173-A1 Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof TTPA, SDHA, SDHB ALDH1A1 376/4885CYP3A4 1155/4885SMN1; SMN2 1039/4885
US-20130195983-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABCB1, SLC47A1, ABCC1 ALDH1A1 1501/4885CYP3A4 2943/4885SMN1; SMN2 1545/4885
US-20020010348-A1 Methods for preparing new taxoids and pharmaceutical compositions containing them TOP1, TMSB4X, TUBB1 ALDH1A1 3366/4885CYP3A4 813/4885SMN1; SMN2 1257/4885
US-20190151469-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES RNASE1, RNMT, TRDMT1 ALDH1A1 3715/4885CYP3A4 4885/4885SMN1; SMN2 406/4885
US-20190192661-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT CUTA, KRT18, SLC38A7 ALDH1A1 4452/4885CYP3A4 4851/4885SMN1; SMN2 2690/4885
US-20200392289-A1 Biodegradable Polymer and Use Thereof PBK, PUF60, CD47 ALDH1A1 4658/4885CYP3A4 4745/4885SMN1; SMN2 3413/4885
US-20010051736-A1 New taxoids produced by esterification at position 13 of taxoid ring; antitumor and antileukaemic properties MCL1, RPL15, RPL22 ALDH1A1 1348/4885CYP3A4 269/4885SMN1; SMN2 1845/4885
US-20090263483-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABCB1, SLC47A1, ABCC1 ALDH1A1 1501/4885CYP3A4 2943/4885SMN1; SMN2 1545/4885
US-20020120170-A1 Conversion of alpha,beta-unsaturated ketones and alpha,beta-unsaturated esters into alpha-hydroxy ketones and alpha-hydroxy esters using Mn(III) catalyst, phenylsilane and dioxygen HSD17B7, CYP17A1, HSD17B1 ALDH1A1 505/4885CYP3A4 112/4885SMN1; SMN2 2845/4885
US-20090311249-A1 Capecitabine Combination Therapy RICTOR, MTOR, EIF4E ALDH1A1 3958/4885CYP3A4 1137/4885SMN1; SMN2 2781/4885
US-20060216265-A1 Dendrimers as molecular translocators SLC29A1, SLC29A2, TSPO ALDH1A1 954/4885CYP3A4 1489/4885SMN1; SMN2 3103/4885
US-20140212362-A1 COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS OAT, CUTA, KRT18 ALDH1A1 2297/4885CYP3A4 1320/4885SMN1; SMN2 4517/4885
US-20080119421-A1 Process for treating a biological organism BUB1, BOD1L1, BUB1B ALDH1A1 3809/4885CYP3A4 4188/4885SMN1; SMN2 315/4885
US-20140302157-A1 NANOPARTICLE FORMULATIONS AND USES THEROF TSG101, HDGF, TP53 ALDH1A1 2973/4885CYP3A4 4305/4885SMN1; SMN2 1853/4885
US-20250213724-A1 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES RNASE1, RNMT, TRDMT1 ALDH1A1 3715/4885CYP3A4 4885/4885SMN1; SMN2 406/4885
US-20170172975-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABCB1, SLC47A1, ABCC1 ALDH1A1 1501/4885CYP3A4 2943/4885SMN1; SMN2 1545/4885
US-10624877-B2 Composition and method for treatment of symptoms associated with various skin conditions OAT, CUTA, KRT18 ALDH1A1 2297/4885CYP3A4 1320/4885SMN1; SMN2 4517/4885
US-20220125820-A1 DRUG FORMULATIONS FOR CANCER TREATMENT RNMT, NTPCR, SYNCRIP ALDH1A1 2522/4885CYP3A4 4750/4885SMN1; SMN2 451/4885
US-20050234018-A1 Drug delivery to the back of the eye PDE6C, PDE6D, EYA2 ALDH1A1 860/4885CYP3A4 1201/4885SMN1; SMN2 4543/4885
US-20030149268-A1 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators AR, SHBG, NR5A1 ALDH1A1 3449/4885CYP3A4 411/4885SMN1; SMN2 4770/4885
US-20050186267-A1 Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin PDCD2L, SBDS, SORD ALDH1A1 2947/4885CYP3A4 289/4885SMN1; SMN2 1882/4885
US-20110293690-A1 Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof PGF, TNF, CD68 ALDH1A1 2709/4885CYP3A4 2857/4885SMN1; SMN2 3267/4885
US-20070027129-A1 Water-soluble compound MKI67, CCNI, PCNA ALDH1A1 4736/4885CYP3A4 4611/4885SMN1; SMN2 776/4885
US-20140080901-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABCB1, SLC47A1, ABCC1 ALDH1A1 1501/4885CYP3A4 2943/4885SMN1; SMN2 1545/4885
US-10293058-B2 RNA containing composition for treatment of tumor diseases RNASE1, RNMT, TRDMT1 ALDH1A1 3715/4885CYP3A4 4885/4885SMN1; SMN2 406/4885
US-20200306284-A1 DRUG FORMULATIONS FOR CANCER TREATMENT RNMT, NTPCR, SYNCRIP ALDH1A1 2522/4885CYP3A4 4750/4885SMN1; SMN2 451/4885
US-20030083497-A1 Taxoids, their preparation and pharmaceutical compositions containing them TBXA2R, CBR1, CBR3 ALDH1A1 665/4885CYP3A4 126/4885SMN1; SMN2 3035/4885
US-20110091549-A1 Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels PDE10A, PDE2A, PDE3A ALDH1A1 2245/4885CYP3A4 1035/4885SMN1; SMN2 4685/4885
US-20070092549-A1 Water-soluble compound MKI67, CCNI, PCNA ALDH1A1 4736/4885CYP3A4 4611/4885SMN1; SMN2 776/4885
US-20180289620-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABCB1, SLC47A1, ABCC1 ALDH1A1 1501/4885CYP3A4 2943/4885SMN1; SMN2 1545/4885
US-20050095197-A1 Anti-mitotic compound MKI67, NUMA1, PCNA ALDH1A1 4768/4885CYP3A4 4745/4885SMN1; SMN2 1521/4885
US-20080221020-A1 Dendrimers as Molecular Translocators SLC29A1, SLC29A2, TSPO ALDH1A1 954/4885CYP3A4 1489/4885SMN1; SMN2 3103/4885
US-20220096645-A1 POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY TOP2A, TOP1, TOP2B ALDH1A1 2224/4885CYP3A4 2135/4885SMN1; SMN2 992/4885
US-20010021783-A1 New taxoids, their preparation and pharmaceutical compositions containing them CBR1, TBXA2R, CBR3 ALDH1A1 640/4885CYP3A4 122/4885SMN1; SMN2 3140/4885
US-20220339259-A1 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF FABP2, SLC27A1, SLC27A2 ALDH1A1 3875/4885CYP3A4 1475/4885SMN1; SMN2 3087/4885
US-20050019404-A1 delivering medical equipment having layers or zones containing drugs, to the target tissues for release of drugs; tissue-targeted therapy; drug delivery PLAUR, ABCB1, MATR3 ALDH1A1 1792/4885CYP3A4 359/4885SMN1; SMN2 1552/4885
US-20020087013-A1 Methods for preparing new taxoids and pharmaceutical compositions containing them TOP1, TMSB4X, TUBB1 ALDH1A1 3366/4885CYP3A4 813/4885SMN1; SMN2 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.